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This study was conducted with a combination of
questionnaires, interviews, enquiry-letters and literature-search.
The results indicate that there is a demand for testing and
certification services on traditional Chinese medicines from the
local herbal industry. This demand is currently rather low, but is
expected to increase in the near future. Similarly, several
government departments have the need to check the authenticity,
purity, quality and toxicity of the Chinese medicines circulating
in Hong Kong. However, many of them indicate that they have no
access to a dependable source of testing and certification services
on these commodities. It should be noted that, whether or not they
have to deal with Chinese medicines, all the respondents from the
government unanimously vote for stricter regulation on these
medicaments. If the Basic Law to be drafted is to match the
principle of Article 21 of the Constitution of the People's
Republic of China, stricter regulation on Chinese medicines is
likely to be established and enforced, which in turn would
intensify the demands for testing and certification services from
the local herbal industry. On the hand, about half of the fifteen
countries contacted in this study show that they either are
requiring or would prefer to have some form of testing and
certification from the importers and/or importing countries.
Responses from the local testing and certification laboratories
3
revealed that the majority of them do not offer such services on
Chinese medicines. Even in those who do, their services are very
limited and incomprehensive.
The Medicinal Material Research Centre of The Chinese
University of Hong Kong is considered an appropriate unit to look
into the possibility of offering such services, since it is well
equiped and experienced in the field. However, the currently low
demand for the local herbal industry is not likely to generate
enough revenues for the Centre to maintain breaking-even.
Nevertheless, the Centre, being a unit of a non-profit
organization, would be in an excellent position to accept endowment
funds and government contracts to lay foundations for the
aevelopment of testing methods and standards for such services as
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Traditional medicine is gaining momentum nowadays for two
main reasons. First, people in industrialized countries have
developed a phobia towards synthetic drugs, simply because of the
irany undesirable and sometimes drastic toxic effects. The growing
sentiment in favour of a return to the use of effective crude
botanicals for the treatment of some diseases arises out of a
knowledge, at least in the United States, that synthetic drugs lead
to iatrogenic diseases that cost the American public about US$2
billion more annually in added health care costs and also an
increase of 5 days for an average hospital stay (Farnsworth 1980).
Second, the World Health Organization has decided to break away
from its long-established principles and recognise the contribution
of traditional medicines to the health-care of people, especially
those in developing countries. In May 1978, at the Thirty-First
World Health Assembly, a recommendation on Drug Policies and
Management: Medicinal Plants was made to initiate programmes
designed to utilize more effectively medicinal plants in health
care systems of the developing countries. Scientific research
vadertaken in these programmes together with other non-WHO projects
have accumulated more and more convincing results to indicate that
many herbal remedies do have a sound scientific basis for their
claims.
Among the many systems of traditional medicines, Chinese
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medicine is the most well-developed and documented. It is the
accumulated experience and wisdom in utilizing natural products by
the Chinese people for the prevention of diseases and treatment of
ailments. These knowledge in the therapeutic values of natural
products were systematically documented and gradually refined in a
series of pents'aos (Chinese herbals) issued in the last two
millennia and also in the many works on Chinese materia medica
published in the last thirty-odd years (But et al 1980 Cheung'et
al 1983). Today, Chinese medicine is still playing an important
role in providing health care to people in China as well as in
places where Chinese culture has a strong influence. Recent
scientific studies on Chinese medicines have continually reported
the successful isolation of active ingredients from many medicinal
plants. A rough count of the 104 new drugs developed in mainland
China between 1949-1979 showed that 65% of the new pharmaceuticals
originated directly or indirectly from medicinal plants (Peng
Wang 1981). The successful implementation and integration of
traditional and modern medicinus in China has deeply impressed man
scientists and laymen in developed countries. Hence, besides
people in Japan, Korea, and Southeast Asia where Chinese medicine
has been adopted for centuries, many of those in western countries
are also seeking relief of ailments from Chinese medicines.
However, to gain access to those markets, it is necessary to
provide evidence of safety, authentication of origin, and quality
control in order for any traditional medicinal preparations to
clear their respective customs and drug-control agencies. It is
foreseeable that requests for authentication, certification of the
contents and origins, and safety tests of both crude drugs
and over-the-counter (OTC) preparations will come from成 药
药 材
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foreign customs offices and drug control agencies, as well as from
foreign herb dealers importing drugs from Hong Kong. We suppose
that there is or will have an external demand from foreign
countries.
Here in Hong Kong, the government has relied on modern
medicines as the standard and source of health-care for people in
Hong Kong. Every year, a large budget is appropriated for the
education of modern medicine and for medical services with modern
medicine. For the financial year 1983-4, the Medical and Health
Department's estimated expenditure is HK$1,771.6 million. In
addition, subventions totalling about HK$915.2 million are being
made to many non-government medical institutions and organizations
(Anon. 1984). Western medicines are readily available to all
citizens of all social strata. However, besides modern medicines,
people in Hong Kong still seek relief from traditional Chinese
medicine. According to the surveys conducted by Professor Rance
Lee (1980) of the Institute of Social Studies, The Chinese
University of Hong Kong, about 60% of the local population would
take Chinese medicine as an alternative or additional source of
health care. Moreover, this belief in traditional Chinese medicine
cuts across the various social strata as defined by the differences
in education level, financial capability and age. Calculations
based on figures presented in the 1983 Hong Kong Trade Statistics
showed that about HK$1,400 million of Chinese medicines, which
include crude drugs, over-the-counter preparations and medicated
wines, were'imported into Hong Kong about half of the imports were
consumed locally, and the remaining re-exported.
Although traditional Chinese medicine has received popular
support by the local populace, the government remains indifferent
4to this alternative system of health-care, and allows a 'live and
let live' policy toward it. According to Chapter 138, the Pharmacy
and Poisons Ordinance, nothing in that Ordinance shall apply to
the sale, manufacturing, dispensing or compounding of traditional
Chinese medicines as listed in the Chinese Herbal Material Medica
or which are made from herbs customarily used by the( 本 草 纲 目 ）
Chinese people. This excessively lenient policy would allow a
free-for-all situation and frequently undesirable adulterations and
also distrust in Chinese medicines. Requests to review and rewrite
the Ordinance were repeated from time to time by people from the
medical and academic circles, private sectors, and even the
Umelco. However, the Medical and Health Department insisted that
there is no need to revise the policy. Under the present
situation, the quality and stability of traditional Chinese
medicines are disciplined only by the herb dealers' associations.
With no other body to supervise the herb industry, some foreign
customs offices have to rely on the Hona Kona Chinese Meaieine
Merchants Association to certify the origin（ 香 港 中 药 联 商 会 ）
and authenticity of crude drugs re-exported from Hong Kong.
Inspection of some samples of the certificates has found many
mistakes in them (Appendice 1 and 2). For OTC preprations, since
there is no qualified body to certify them, they are either
'smuggled' into other countries or unable to clear the customs and
drug control agencies.
With the coming changes in the political scene, this lenient
situation has to be changed. In the first place, the Basic Law to
be drafted may have to match the principle of developing both
modern and traditional Chinese medicine.... for the health of the
people as prescribed in article 21 of the Constitution of the
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People's Republic of China. As prescribed in the PRC Constitution,
traditional Chinese medicine has a status equal to that of modern
medicine. To avoid misuse, abuse and adulteration of both modern
and traditional medicines, the Chinese government has established
institutes of drug control in major cities of all provinces and
autonomous districts to inspect both modern and traditional
medicines according to the standards of the Pharmacopoeia of the
People's Republic of China and other local standards. It is
foreseeable that similar set-ups have to be arranged here very soon
in order for Hong Kong to keep in line with the PRC Constitution
and the practice of drug control in China. Even if the government
would like to stall this trend, the local herblists, who have been
suffering from discrimination tinder the present system, would call
for the change. The trouble ie that the government does not have
the ability and finance to take up this task in the transitional
period. We believe that the Chinese University with a strong team
and sophisticated instruments can function as an excellent buffer
and body to handle the task of authenticating and certifying
Chinese medicines, both crude drugs and OTC preparations. Not only
is this arrangement more cost-effective, but also is more realistic
in the transitional years. We expect that an internal demand
exists and would come from both the government and local dealers.
6CHAPTER II
OBJECTIVES OF THE STUDY
The objectives of this preliminary exploratory survey on the
feasibility of establishing a testing and certification centre,at
the Chinese Medicinal Material Research Centre (CMMRC) of The
Chinese University of Hong Kong are:
1) to identify if there is a need for the services to
authenticate, standardize, and certify traditional
Chinese medicines from
a) local herb dealers and OTC drug manufacturers,
b) the Hong Kong government, and
c) foreign importers and government agencies
2) to determine the strength and weakness of the CMMRC
concerning its capability, resources, and needs in
meeting the needs and offering services to authenticate,
standardize, and certify traditional Chinese medicines
and
3) to check if there are any other sources of such services
in Hong Kong (i.e. aompetitors).
7CHAPTER III
MI4THODOLOGY
The study is conducted by means of Questionnaires and
interviews. In order to assesu the demand of certification
services for Chinese medicines, we tackle the problem from three
angles:
A) Local Demand by the Herbal Industry
A selected group of representative members in the following
two areas of the herbal industry is selected: 1) dealers
(importers, exporters, and wholesalers) of both crude and OTC
Chinese medicines, and 2) Manufacturers of OTC drugs.
A total of ten members, two of whom are officers of the
associations of merchants of Chinese medicines, are selected.
Roughly, four of the ten members belong to the first group of
dealers. Another four are manufacturers or at least have their own
lines of production labelled in their special brand. The remaining
two belong to both groups as their business involves both areas.
Questionnaire A (Appendix 3) was devised to find out from
the herbal industry whether or not they need any testing and
certification services for the import, sale, and export/re-export
of both crude and OTC Chinese medicines (Questions a and b of
Questionnaire A respectively). In addition, Question c aims to
determine'if the industry would prefer to having testing and
8
certification services in order to expand their markets and
penetrating into new markets. We also asked in the Questionnaire A
the name of the countries that require such services, the degree of
satisfaction with existing testing centres, and the number of
testings needed each year.
Topics included in each question concern authentication and
identification of the drugs to their original and/or constituent
plants, organoleptic testing, residues of pesticides, levels of
heavy metals, kinds and amounts of active ingredients, infestation,
labelling and packaging, toxicity, efficacy, and quality control.
B) Foreign Demand
We checked the most recant copy of the Hong Kong Trade
Statistics (i.e. 1983) when we first started the project, to
extract all the export and re-export statistics of crude and OTC
Chinese medicines (Medicinal wines are. lumped under OTC medicines
in the questionnaires) (appendix Tables 1-6). A total of 24
countries, representating both developed and developing countries
and including all the major buyers, were selected.
Enquiries into a) the regulations and laws on traditional
medicines, herbs, and health foods of each country, b) names and
address of herbal importers and associations, c) import statistics,
and d) opinions on whether or not it is of value to offer testing
and certification services for Chinese medicines.
The enquiries were sent to.Consul-Generals or Commissioners
of those countries, if represented i.n Hong Kong, and then to the
departments and authorities they suggested in their replies. If no
Consul-General or Commissioner is.avai-lable in Hong Kong, the
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enquiries were directed to the Department of Health and/or related
agencies.
A few enquiries were sent to contacts known to be in the
herbal industry in foreign countries (e.g. Japan, Italy, and
Sweden).
The purpose is to find out if the laws and regulations on
the import and distribution of traditional medicines, herbs and OTC
drugs would demand some form of testing and certification from the
suppliers. Chinese medicines may be presented in any of the three
forms, i.e. traditional or naturopathic or homoeopathic medicines,
herbs and OTC drugs. We did not ask for information on modern
pharmaceuticals, although a few OTC drugs might have gained such
status in foreign countries. It is because it would be almost
impossible for us to isolate those few cases from the other modern
pharmaceuticals. Moreover, it is fair to say that all modern
pharmaceuticals,would need some form of testing and certification
in order to gain approval for importation and distribution.
C) Demand by Local and Foreign Policy-Makers
Policy-makers can change and create laws and regulations
that would require testing and certification of Chinese medicines.
Their attitudes as well as their current job areas may tell whether
or not testing and certification is needed now or in the future.
These policy-makers may also want the services themselves, such as
in cases of legal dispute, suspicion of adulteration and spiking
with scheduled poisons, and interception by Customs.
For the local authoritiou, Questionnaire B (Appendix 4) was
prepared and sent to thirteen officials of key positions in various
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departments that may have to deal with Chinese medicines, whether
as drug, food, narcotics, poisons, agriculture products, imports
and exports, and industrial commodities. We want to find out from
them if their departments need testing and certification services
on Chinese medicines and also their sources of services. In
addition, we try to find out it they know of any current demand and
predict any increase in demand for testing and certification
services. Finally, we also asked them for their personal opinions
on whether or not Hong Kong should have stricter regulation on the
authenticity, quality and safety of Chinese medicines. This last
question may find out if there can be stricter requirements
lavished by the government, which in turn would lead to a higher
demand for such services.
On the other hand, by moans of Questionnaire C (Appendix 5)
and unstructured interviews we also checked the services offered by
existing testing and certification laboratories in Hong Kong. They
constitute the 'competitor' segment. If they are providing such
services, there is no need for the establishment of any testing and
certification unit in the Chinese Medicinal Material Research
Centre. If these 'competitors' provide only a few of the possible
and important services, there would be areas or niches where the
Centre should concentrate on. In addition, we also asked if those
laboratories may intend to offer such services in the future if not
available at the moment. It should be noted that in Questionnaire
A for the local herb industry we asked if they are satisfied with
the services provided by existing laboratories. The answers to
this last question may also indicate to us whether there is any
demand for better services from these laboratories or from a new
laboratory.
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Finally, we tried to astuess the strength and weeakness of
the Chinese Medicinal Material Research Centre of The Chinese
University of Hong Kong, to see if its manpower, expertise,




DEMAND FOR TESTING AND CERTIFICATION SERVICES
(I) LOCAL HERBAL INDUSTRY
Questionnaire A (please refer to Appendix 3) was sent to
each of the ten selected repreiientatives of the local herbal
industry, with stamped return-invelope. The ten respondents
included:
(a) four dealers who are known to handle both import-export and
wholesaling business with Chinese medicines
(b) four manufacturers of OTC drugs, either with factory of their
own or through contracts with factories in mainland China, and
(c) two others who handle both import-export-wholesales and
manufacturing.
Two of the selected representatives, one being a dealer and
another being a manufacturer, refused to answer our questionnaire
when we called on them for response. These two representatives are
discarded from our analysis.
All the remaining eight respondents replied by giving us
their opinions either by returning the questionnaire or by
answering in phone. Their answers are summarized in Tables 4.1 to
4.6. The percentages of opinions are based on a maximum of eight
answers.
The percentages of the respondents indicating that they need
to have their crude drugs and OTC drugs tested/certified in import,
local sales and re-export, as shown in Tables 4.1 and 4.2, are
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rather low. For crude drugs, the emphasis appears to be placed on
species authentication and on molding and infestations. For OTC
drugs, the emphasis inclines toward molding and infestation,
foreign substances and heavy mutals. Roughly speaking, the herbal
industry pays slightly more attention to having OTC drugs tested
and certified than to crude drugs, particularly in local sales and
re-exports to western countrieu. Overall speaking, the need is
only minimal, when we check the frequency of employing such
services by the respondents each year (Table 4.6).
One thing surprising to us is that the percentages in Table:
4.1 and 4.2 indicate the herbal industry appears to undertake more
checkings and testings for re-exports to non-western countries that
to western countries. This emphasis is partly supported by the
high percentages of respondents showing that Japan (75%), Korea
(63%) and Taiwan (50%) requires testing/certification services on
Chinese medicines to be imported (Table 4.4).
Majority of the respondents answered in the affirmative to
questions concerning the need of such services for them to expand
their markets and penetrate into new markets (Table 4.5). Seven
out of eight respondents showed the need for quality control
(88%). Two-thirds prefer to have testing and certification
services for residue pesticides, heavy metals and the content of
active components (75%). Slightly more than half of the
respondents show interest in species authentication for crude
drugs, checking the types of active components, molding and
infestation, as well as foreign substances (63%). Half of the
respondents indicate need for authentication of species composition
in OTC drugs, and for packaging and labelling (50%). Only 38% of
the respondent show concern for organoleptic check and efficacy.
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Tt is surprising to find only three of them want to confirm their
claims for efficacy.
Finally, majority of the respondents are not satisfied with
the services provided by existing testing and certifying
laboratories (Table 4.5). Most of the unsatisfied respondents find
them incapable of certain specific tests, especially in checking
the active components. At least one respondent shows doubts on the
inconsistence of testing results conducted by existing laboratories
sometimes on one single batch.
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TABLE 4.1
PERCENTAGE OF RESPONDENTS FROM LOCAL HERBAL INDUSTRY SHOWING
THAT THEY NEED TO HAVE THE CRUDE DRUGS TESTED/CERTIFIED
IN THE MAJOR LINKAGE POINTS OF TRADING
Re-export Re-export
Local to Westerr to Other
Testing/Certification Services I mporl Sales Countries Countries
1 Species authentication 50% 13% 0% 50%
2 Oranoleptic check 25% 0% 13% 25%
3 13% 0%Residue pesticides 13% 13%
4 Heavy metals 0% 0% 13% 13%
5 Types of active components 13% 0% 0% 25%
6 Content of active components 13% 0% 0% 13%
7 Molding and infestation 63% 25% 25% 50%
8' Foreign substances 38% 0% 25% 25%
9) Toxicity 13% 0% 13% 13%
101 Efficacy 13% 0% 0% 13%
09411l Quality control 38% L3% 0%
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TABLE 4.2
PERCENTAGE OF RESPONDENTS FROM LOCAL HERBAL INDUSTRY SHOWING
THAT THEY NEED TO HAVL THE OTC DRUGS TESTED/CERTIFIED
IN THE MAJOR LINKAGE POINTS OF TRADING
Re-export Re-export
Local to Western to Other
Testing/Certification Services Import Sales Countries Countries
1) Species composition 25% 13% 0% 50%
authentication
2) Organoleptic check 25% 13% 13% 38%
0% 0%3) Residue pesticides 13% 25%
4) Heavy metals 25% 25% 25% 25%
5) Types of active components 0% 0% 0% 13%
6) Content of active components 13% 13% 0% 25%
7) Molding and infestation 50% 25% 38% 50%
8) Foreign substances 38% 25% 25% 38%
9) Toxicity 13% 0% 13% 13%
.0) Efficacy 13% 25% 13% 15%
1) Quality control 13% 25% 13% 38%
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TABLE 4.3
PERCENTAGE OF RESPONDENTS FROM LOCAL HERBAL INDUSTRY SHOWING
THAT TESTING/CERTIFICATION SERVICES ARE NEEDED IN ORDER
TO EXPAND MARKET AND PENETRATING INTO NEW MARKETS
Percentage of
Testing/Certification Services Affirmative Answers
1) Species authentication 63%
2) Species composition authentication 50%
3) Oranoleptic check 38%
4) Residue pesticides 75%
5) Heavy metals 75%
6) Types of active components 63%
7) Content of active components 75%
8) Molding and infestation 63%
9) Foreign substances 63%
10) Packaging and labelling 50%
11) Toxicity 63%
11) Efficacy 38%
12) Quality control 88%
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TABLE 4.4
PERCENTAGE OF RESPONDENT'S FROM LOCAL HERBAL INDUSTRY SHOWING
FOREIGN COUNTRIES REQUIRE TESTING/CERTIFICATION
SERVICES ON CHINESE MEDICINES
Percentage of Respondents
Indicating the Need for
Testing/Certifying Services
Country For Exportation to
1) China mainland 25%








LOCAL HERBAL INDUSTRY'S SATISFACTION WITH SERVICES
PROVIDED BY EXISTING TESTING AND
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DEMAND FOR TESTING AND CERTIFICATION
SERVICES (II) FOREIGN DEMAND
Based on the lists of countries to which Hong Kong has
exported or re-exported Chinese medicines, we have selected the
following countries as our targets for enquiry into their
regulations on traditional medicines,- herbs, and health foods:
Australia, (Canada), China maiiiland and Taiwan, France, Federal
Republic of Germany, (India), Indonesia, Italy, Japan, (Republic of
Korea), (Malaysia), Netherlandu, New Zealand, (Nigeria), Norway,
(Philippines), South Africa, Singapore, Sweden, Switzerland,
(Thailand), United Kingdom, and the United States of America. The
enquiries were distributed to the supposedly relevant authorities
of each country, including the Consulates, Departments of Health,
Customs, and Statistics, as well as to herb dealers we have met.
Reponses and the amount of information made available to us
were very varied. A few countries, such as Australia, the Federal
Republic of Germany, Japan and New Zealand, are very helpful and
indeed earger to cooperate with us. Most other countries supplied
us with only bits and pieces of information, insufficient to give
us a complete picture of their situation, making it necessary for
us to rely on second-hand sources sometimes casually mentioned in
international journals or buried in libraries. In the case with
Indonesia, no response was received from the Department of Health,
even though the Indonesian Consul-General here had made the
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arrangement fortunately, a country report on the policy and
regulations of Indonesia on traditional medicines was obtained by
us in a Workshop conducted in 1983 by the Commonwealth Science
Council in Lucknow, India. Authorities in Sweden and Italy
provided us with little information however, our contacts of the
herbal industry there were very helpful in summarising and
translating the relevant portions of the regulations in their
countries. No information was made available to us from the
countries marked in brackets above. The Commissioner of Canada
referred us to a Department in Canada, which did not responded to
our enquiry. The Commissioner of India and the Consul-General of
the Republic of Korea forwarded a copy of our enquiry to their
countries no further news was received from them after a period of
four months.
The situation is not as simple as we imagined at the
beginning of the study. Not to say the headache in relaying our
enquiry from one department to another, the information made
available to us are sometimes conflicting. Moreover, the laws are
frequently written in a language outside of common use by any of
us, e.g. Swedish and German. Nevertheless we are able to summarise
the situation in most of the countries mentioned above. A country
by country profile is presented in the following sections in this
Chapter.
A) Australia
Australia is a major buyer as i,t..imports a fairly sizeable
amount of Chinese medicines from Hong.:'Kong. In 1983, the following
amounts of crude and OTC drugs were.-supplied by Hong Kong: Licorice
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roots $28,684, Angelica $200,420, Codonopsis $22,324, Astragalus
$4,400, Dioscorea $3,588, Chry8t-Anthemum $34,760, Boxthorn fruit
$44,128, Ginseng $384,107, Sandlewood $2,100, Cloves $4,064, Dried
Ginger $9,702, Thyme and other spices $166,249, Seeds of Anise and
other species $48,130, Cinnamon $1,835, Pepper and Pimento $7,594,
Plants for Perfume and Pharmacy $2,136,654, OTC drugs $1,074,638,
and Chinese medicinal wines $282,832.
The Department of Health controls the importation of
therapeutic substances into AuiLralia under the provisions of the
Customs (Prohibited Imports) Roi.lulations, the Therapeutic Goods
Act, the Quarantine Act, and the Wildlife Protection (Regulation of
Exports and Imports) Act of 1982. These legislations are designed
to ensure that therapeutic substances imported into Australia
conform to acceptable standards of,quality, safety and efficacy.
To this end, data are required relating to chemistry and quality
control, as well as toxicology and clinical studies to justify the
claims made for the product. The Department assesses each
application on its merit and reserves the right to ask for a full
submission or only a part of the supporting documents.
The Department of Health has compiled a Herbal Importation
List to control the importation of herbs (crude) and herbal
remedies (OTC drugs). The list classified herbs into two
categories. The first category refers to herbs not for therapeutic
use, which includes culinary herbs and herbs and herbal
preparations not for therapeutic use. Culinary herbs are listed in
Section 1 of the List, and no application is required for their
importation. For herbs and herbal remedies not for therapeutic
use, importation of these substances may be effected by means of a
declaration on the Customs entry to the effect that the goods are
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not for therapeutic use. The second category refers to herbs and
herbal products intended for therapeutic uses. The plants
recognised to have mild therapeutic effects are listed in Sections
2 and 3 of the List. An application for approval for importation
of these substances is required for these items and should include
(a) the name and address of the manufacturer and/or supplier, (b) a
certificate of analysis where feasible and/or identity of a typical
batch of the herbal remedy, including the botanical name and
commonly used English name, (c) details of the extraction process
and a statement of content of the final product, (d) an assurance
that a certificate of analysis and/or identity as detailed in (b)
will accompany the documentation for each consignment for two years
and be available for inspection on request by departmental
officers, and (e) two copies of labels and where utilized, package
inserts, promotional material or any other relevant product
literature (or a draft thereof), together with an assurance that
the labelling or such product literature will not be amended, or
new product literature will not be issued without the consent of
the Department of Health. For the importation of prepackaged or
formulated herbal remedies with plants of mild therapeutic effects
listed in Sections 2 and 3 of the List, the same requirements as
for the importation of the crude materials mentioned above are
applicable. In addition, when considered necessary by the
Department, data to substantiate the therapeutic claims made for a
formulation may be needed.
For the importation of,hi,rbs and herbal remedies not
included in the Herb Importatioli List, importers will be required
to submit to the Department for evaluation data in accordance with
Department form NDF4, or such purtions of that data as are advised
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by the Department for specific products. If the data prove
satisfactory, permission to import will be granted with
restrictions to the end-use of these imports for the substantiate(
indications only. An application for approval for importation of
prepackaged or formulated herb(il remedies of plants not included in
the List would require the samu set of data as well as the
certificates of analysis and ol..her related assurances are to be
submitted.
In addition, herbs are iiubject to normal quarantine contro:
procedures. Moreover, labels lend outer cartons of finished
products are required to display the followings: (a) name and
street address of the Australian distributor, (b) expiry date and
storage details, (c) batch number, expressed as B or Batch No.
followed by the batch number, and (d) the botanical nomenclature
and quantity of each herb per unit dose to be indicated.
So far as we can read from the Australian regulations,
certification of crude and OTC Chinese medicines due for shipment
to Australia is required.
B) China
Both mainland China and Taiwan are major buyers of our
exports and re-exports of Chinese medicines. The 1983 Hong Kong
Trade Statistics revealed that mainland China imported extensively
from Hong Kong for $179,025's worth of Poppy straw, $97,084 of
Ligorice root, $4,015,081 of Angelica, $1,142,023 of Codonopsis,
$4,264,408 of Astragalus, $133,891 of Dioscorea, $457,571 of
Rehmannia, $938,792 of Chrysanthemum, $347,118 of Boxthorn fruit,
$76,272,746 of Ginseng, $522,300 of Cassia, $1,156,225 of
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Sandlewood, $1,053,856 of ivory waste, $82,343 of Shell Mollusc,
$1,054,105 of Horns and Antlers, $220,359 of Birds nest, $494,895
of Cloves, $5,325,028 of Cardamons, $138,000 of Nutmeg and Mace,
$1,319,470 of Saffron, $1,642,445 of Thyme and other spices,
$290,155 of Pepper and Pimento, $60,908,992 of Plants for Perfume
and Pharmacy, $22,966,188 of OTC drugs, and $58,200 of Chinese
medicinal wine.
However, Chinese authorities in the mainland contacted in
this study were reluctant to disclose to us clear-cut and definite
answers. This reluctance might be traceable to the fact that the
PRC has just revised its regulations on pharmaceuticals and
traditional medicines last September. On September 20, 1984, in
the seventh meeting of the Executive Committee of the Sixth Meeting
of the People's Representatives, the Pharmaceuticals Management Law
of the PRC was passed. This Law only outlines the major issues
without much details on specifics. In section 28 of the Law, the
pharmaceuticals imported should be inspected and approved before
importation by laboratories approved by the Department of State.
Here the Law does not make any provision for exemption for crude
and OTC traditional medicines. If this is truly the case,
suppliers of crude and OTC drug. may have to provide details on the
origin, quality, and efficacy of: their products before gaining
approval from the Department of State. However, we doubt if
mainland China would go for that extreme. Our understanding
through informal discussion with agents of testing laboratories in
mainland China showed that they are cooperating with the Customs
Department. Some sort of certification is thus necessary, and
indeed one of the response from the OTC drug industry to our
questionnaires indicated that mainland China does require from them
27
certifications on quality analysis.
So far as we know, the Pharmacopoeia of the PRC (1977
edition) covers 637 crude plant drugs, 158 plant extracts or
isolated ingredients, 46 crdue animal drugs, 8 animal extracts, and
33 inorganic compounds (But et al. 1980). It also accepted 270
multi-itemed prescriptions for the preparation of formulated OTC
drugs. Currently, this Pharmacopoeia is under revision and the new
edition may be issued next year until then, the standards set in
the monographs in this Pharmacopoeia are used as the criteria for
inspection.
Taiwan relies heavily on Hong Kong for the supply of
traditional medicines originated from mainland China. In 1983,
Taiwan imported from Hong Kong $1,505,942's worth of Liquorice
root, $10,291,459 of Angelica, $7,456,961 of Codonopsis,
$19,084,609 of Astragalus, $333,652 of Dioscorea, $2,753,175 of
Rehmannia, $21,200 of Chrysanthemum, $3,957,251 of Boxthorn fruit,
$24,877,881 of Ginseng, $8,589,275 of Cassia, $2,604,827 of
Sandlewood, $260,778 of Shell Mollusc, $352,517 of Horns and
Antlers, $188,612 of Cloves, $71,700 of Cardamons, $50,000 of Thyme
and other spices, $44,700 of Seeds of Anise and other species,
$327,628 of Cinnamon, $317,269,350 of Plants for Perfume and
Pharmacy, and $6,495,146 of OTC drugs.
The laws governing the practice, manufacture, import, and
sale of Chinese medicine are summarised in the Industry of
Traditional Chinese Medicine in Taiwan Province ( 台 湾 省 中 医 药 业 要 概 ）
(Chen 1965). Most of the regulations covering modern medicines
appear to be equally applicable to Chinese medicines, except where
there are exemptions or special provisions. Article 6 of the
Regulation on the Pharmaceutical Industry of Taiwan specified that
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importers should report to the Department of Health in city or
prefecture the name, quantity, composition and manufacturers of all
imported pharmaceuticals, and have them inspected and approved by
the Department before selling them in Taiwan. When submitting
samples for inspection, the Regulation on OTC Drugs does not
mention any certificates rather the Department of Health will test
the samples and charge an inspection fee. Moreover, article 3 of
the same Regulation on OTC Drugs made provisions for the exemption
of those OTC drugs that are prepared and named according to
existing classic Chinese prescriptions. There is no reference to
crude medicines. Fifty percent: of the res ondents to our
Questionnaire A from the local herbal industry indicated
certification is required for the imports of crude and OTC
medicines into Taiwan.
C) France
The use of medicinal plants in France is widespread with
French consumption doubling in quantity between 1970 and 1979
(23,000 tons in 1979). The volume of imports increased during the
same period by 250%, as compared to the increase in French
production by only 70%. In 1983, France imported from Hong Kong
$9,000 of Licorice roots, $16,945 of Angelica, $5,400 of
Codonopsis, $28,000 of Astragalus, $21,475 of Dioscorea, $17,139 of
Rehmannia, $16,768 of Chrysanthemum, $23,951 of Boxthorn fruit,
$276,650 of Ginseng, $96,224 of Birds nest, $7,375 of dried ginger,
$96,380 of Thyme and other spices, $400,228 of Seeds of Anise and
other species, $27,184 of Pepper and Pimento, $285,884 of Plants
for Perfume and Pharmacy, $221,209 of OTC drugs, and $328,144 of
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Chinese medicinal wine.
The French government has.limited the sale of herbal and
medicinal plants on an over-the counter (OTC) basis to an
established list of species. This List, regretfully, is not
available to this study. On the other hand, the use of extracts
from medicinal plants is controlled by the Pharmacopee Francfise
(International Trade Centre UNCTAD/GATT, Anonymous 1982a).
The International Trade Centre UNCTAD/GATT (Anonymous
1982b), in the series of Monographs-on Trade Channels, reminds
suppliers of medicinal plants and extracts that strict laws and
regulations for foodstuffs and pharmaceuticals are equally valid
for medicinal/aromatic plants. These particularly concern
admissible maximum levels of pesticide residues, bacteriological
matter and pharmacological substances. Suppliers are advised to
verify that their particular varieties of plant products are the
commercial varieties that are in demand. French traders reported
that they occasionally receive samples of unmarketable and even
dangerous varieties of plants from unknowledgeable suppliers.
Moreover, it is very important to control all shipments to ensure
that they contain only the plant varieties ordered, with minimal
foreign or extraneous matter. Particular care should also be given
to the consistency of the quality of individual shipments.
Moreover, French importer would generally expect a new supplier to
submit samples, preferably accompanied by a certificate of
analysis. If the supplier's price are competitive, the importer
would submit the samples to hiss clients, who, in turn, will have
them analysed according to their own specifications. If the plant
material corresponds to the requirements of his clients, the
importer will place a trial order. Often, the importer expects the
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trial consignment to be accompanied by a certificate of conformity
from the Ministry of Agriculture or pharmaceutical authorities in
the supplier's country, to the extent that the shipment consists
only of the specific plant material ordered by the importer. In
this context, it is clear that some sort of certification service
is needed for exporting Chinese medicines to%and penetrating the
French markets.
D) The Federal Republic of Germany
The Federal Republic of Germany (hereafter as Germany) is
the largest importer of medicinal plants in Europe with Hamburg
being the centre of world trado in these items. In 1980, Germany
imported 31,452 tons of medicinial/aromatic plants and 805 tons of
alkaloids. About 6,473 tons of the plants and 7,222 tons of
alkaloids were exported and/or re-exported in 1980. In 1983, the
following worth of Chinese medicines were imported from Hong Kong:
$478,155 of Ginseng, $4,920 of Birds nest, $442,815 of dried
ginger, $121,056 of Thyme and other spices, $755,056 of Seeds of
Anise and other species, $111,141 of Cinnamon, $4,319,927 of Pepper
and Pimento, $831,454 of Plants for Perfume-and Pharmacy, and
$136,979 of OTC drugs.
As a market for medicinal plants, Germany is growing,
especially in medicinal infusions, which are marketed through
pharmacies as 'teas' and are drunk to alleviate ailments of the
bowel and bladder. This preference for natural products in Germany
induced a renaissance of the use of many herbal and plant
extractive products in pharmacies (International Trade Centre
UNCTAD/GATT, Anonymous 1982a).
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Homoeopathic remedies are excluded from the revised Drugs
and Pharmaceutics Act of January 1, 1978 (German Foreign Trade
Information Office, Anonymous 1980x). They do not have to
demonstrate their effectiveness for registration with the Federal
Health Administration, as long as they bear no indication of
therapeutic value on the packaging (Steinback 1981).
However, crude drugs and OTC preparations are subject to the
German food laws and regulations, in particular as regards
pesticide residues and harmful'organisms (Plant Protection Law) and
pharmacological substances (Pharmaceuticals Law). Specifications
for some plants are contained in the German and European
pharmacopoeias. Attention should be paid to the quality of
materials, especially the identity of specific plant species and
varieties, content of active substances, grading, foreign and
extraneous matters, and humidity, etc. (International Trade Centre
UNCTAD/GATT, Anonymous 1982c).
Foodstuffs are constantly being checked by government
laboratories. At the point of sale, but also in the manufacturing
plant, officials specially trained for these tasks take samples,
either according to a prearranged plan or in response to complaints
from consumers. These samples are then sent to government
laboratories for analysis. If the analysis performed by the
laboratories shows that the goods do not conform to food laws and
regulations, the importer of the product in question is traced
through all stages of distribution which the product has passed,
and proceedings are instituted-against him. The importer can
exculpate himself only if he proves beyond reasonable doubt that he
proceeded with the care required by the Food Law, i.e. made
adequate checks. It is therefore important for the suppliers of
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crude drugs and OTC preparations to co-operate with the importer in
Germany to ensure that the items supplied meet the standards of
German laws. It should be emphasized that inspection using
organoleptic criteria is not enough. For the protection of the
consumer and the trade as a whole, and not least of all in the
interest of importers, the importer is obliged to engage sworn and
publicly appointed private food chemists, since only these chemists
can find out whether imported food is free from foreign substances,
prohibited colouring matter, heavy metals, pesticides, etc. (Kurz
1980). Guiding principles for (he testing of quality are available
in the Deutsches Lebensmittelbuch (German Food Book).
In addition, a number of laws and regulations would have
effect on crude and OTC drugs, such as:
a) the Aflatoxin Regulation of November 30, 1976, which sets*
maximum level of aflatoxins B1, B2, and G2 allowed in
foodstuffs
b) the Food Labelling Regulation of January 25, 1972/June 19,
1974, which requires an accurate description of prepacked foods
c) the Approved Additives Regulations of December 20, 1977, which
limits the additives and preservatives to a selected list
d) the DDT Law of August 7, 1972/March 2, 1974, and other
pesticide laws (e.g. Regulation Concerning Maximum Levels of
Pesticides in Food of Vegetable Origin of June 21, 1978), which
ban the application of DDT on foods and stables, as well as in
rooms in which food is made, stored or treated
e) the Plant Disease Control Law of October 2, 1975, which intends
to prevent the introduction of plant diseases and certain
pests, and may require a phytosanitary certificate and
f) the Washington Agreement on the Protection of Species
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(Convention on International Trade with Endangered Species of
Wild Animals and Plants of March 3, 1973) would prohibite the
import of such items as rhino horns.
Additionally, the German Food Law does not contain any
special regulations concerning uupices. Hence the tenets of honest
trading practices and consumer expectations are applicable. It
goes without saying that spices have to be free from impurities anc
that they must not be infested with insects and plant diseases. A.C.
far as impurities of animal origin are concerned, attention should
be paid to insects, parts of insects, larvae, maggots, mites,
rodent hairs, etc. The number of germs (bacteria and spores of
mould fungi) shall be small. If treated with ethylene oxide in
cases of high incidence of germs, the spices should have no trace
of ethylene oxide remaining on them (Pesticide Regulation) (Glas
1980).
The Customs Regulations, however, may set another set of
requirements. With regard to some products in the food and
agricultural field, the declaration of the country of origin and
certain purity, blending, and other data are prescribed in order to
protect the consumer. This requirement is applied to at least
herbal wine, and plants and parts of plants.
It is expected that German importers would welcome
Certification services on traditional Chinese medicines.
E) Indonesia
Indonesia is a major buyer of crude and OTC Chinese
medicines from Hong Kong. In 1983, the following amounts of
Chinese medicines were exported and/or re-exported to Indonesia
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from Hong Kong: Licorice roots $16,982, Codonopsis $48,770, Thyme
and other spices $2,170,283, Seeds of Anise and other species
$495,500, Plants for perfume and pharmacy $14,997,701, OTC drugs
$10,179,468, and Chinese medicinal wines $414,181.
Indonesian legislations affecting traditional drugs are:
a) Basic Health Law No. 9, 1960
b) Commodities Law No. .10, 1961
c) Pharmaceutical Law No. 7, 1963
d) Ministrial regulations on (a) the production and distri-
bution of traditional drugs (b) compulsory registra-
tion of traditional drugs (c) packaging and labelling
of traditional drugs and (d) compulsory registration
of imported crude drugs and
e) The Ministerial Decree No. 4278/A/SK/72 and Director
General for Drugs and Food Control Circular Letter No.
1350/A/1977 (Prohibition of Importing and Distributing
Foreign Traditional Drug) in Indonesia.
Before importing crude drugs, an importer has to obtain an
import license from the Ministry of Health. The following data
have to be submitted for approval: name of crude drug, name of the
mother plant and animal, description of crude drug (including
macroscopical, microscopical, and chemical identification, place of
origin, and processing methods).
For OTC drugs, the importer has to submit information on the
composition of the drug, manufacturing method, quality control,
stability data of finished product, and other details of the brand
and manufacturer. However, it should be noted that the Ministerial
Decree No. 4278/A/SK/72 and the Director General for Drugs and Food
Control Circular Letter No. 1350/A/1977 would discourage the import
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of foreign traditional OTC drugs into Indonesia.
Control by the government is through (a) registration data,
(b) inspection of manufacturer (:o check whether the process of
production is in accordance with Good Manufacturing Practice, and
(c) sampling of traditional drums in the market to check if the
products meet with the standard of safety, efficacy and quality
maintained by the Government. A number of laboratories are given
the power to take part in the quality control of traditional
medicines, including the Central Laboratory of Drugs and Food
Control, the Referral Control Laboratory of Drugs and Food Control,
the Provincial Laboratory of Drugs and Food Control, laboratories
of traditional drug industries, and a few university laboratories
(Hargono 1983).
Based on the information available to us in this study?
Indonesia would appear to welcome and may require certification
services for crude and OTC drugs.
F) Italy
The 1983 Hong Kong Trade Statistics showed that Italy
received from Hong Kong $1,506,260's worth of Liquorice root,
$963,000 of Ginseng, $44,720 of Plants for Perfume and Pharmacy,
and $9,450 of OTC drugs. The Consulate General of Italy in Hong
Kong and the Italian Trade Commission do not have any information
on the trade statistics and regulations on herbs and health foods
in.Italy.
The only information supplied to us is from Dr. A. Bonati of
the Inverni della Beffa, a company specialized in the extraction
and sale of medicinal plants in Milan. According to Dr. Bonati,
36
the import and export of crude drugs is completely free only a
phytosanitary certificate is required. On the other hand, the
import of OTC drugs requires registration in Italy with the
Ministry of Health, even when the finished product is already
marketed in other countries. Health foods are freely sold at
chemist's and herb shops provided that no therapeutic property is
claimed.
Based on Dr. Bonati's information, we can conclude that no
certification service on crude drugs except phytosanitation would
be required by the government. OTC drugs not claiming any
therapeutic property also do noL need any certification.
Nevertheless, Dr. Bonati added that Health Authority, industries,
h:-rb dealers and scientists would certainly welcome a
testing/certification centre in Hong Kong to guarantee the quality
of the material due for shipment:. to Italy.
G) Japan
Chinese medicine, a key clement of the Chinese culture and
civilization, has a strong influence in Japan, where a Japanese
version of Chinese medicines has developed and is known as
Kampoyaku. Since Japan is one of the biggest importers of Chinese
medicine, the situation in Japan deserves closer attention. The
following accounts on the market and trade statistics and patterns
of Chinese medicine in Japan are liberally abstracted from the
information summarized by the Japan External Trade Organization
(JETRO 19 834.
Annual consumption of medicinal plants, including those for
non-medicinal'uses (e.g. as spice), is about 40,000 tons, 85% to
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90% of which are imported. A major share of the imports comes from
mainland China (61%), with the balance contributed from the
Republic of Korea (13%), Hong Kong (10%), Europe (5%), Latin
America and North America (5%), Thailand and Taiwan (3%), and other
countries (3%).
The consumption pattern for medicines has changed
significantly in the past ten years. The availability of extracts
which can be taken very easily and the concern of the public over,
the side-effects of newer chemical synthetic medicines have
resulted in a Kampo boom in the recent years. The inclusion of
Kampoyaku under health insurance coverage added new fuel to the
movement. In 1976, medicinal plants became eligible for
prescription under the health insurance program. In 1978, 156
items of medicinal plants were made eligible, and in 1983, 228
items were registered under the health insurance program and
included on the Drug Tariff Schedule. At the beginning, very few
doctors employed Kampoyaku, but now the number of doctors using
such traditional remedies has been increasing along with the demand
from patients.
According to a medical magazine, the Nikkei Medical (Oct.
1981 issue, special supplement), in 1976 only 19.2% Japanese
doctors prescribed Kampoyaku in 1979 and 1981, the percentages
rose to 28% and 37.3% respectively. Of the doctors not prescribing
Kampoyaku at the present, 37.1% of those questioned answered that
}hey will try to use Kampoyaku In the future. The pharmaceutical
industry predicts that the demand for Kampoyaku will continue to be
solid from now on, especially in view of the steady increase in the
number of aged people (65 and above), from 9,188,000 in 1976 to
10,477,400 in 1980, and the general belief that Kampoyaku would
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improve 'weak constitution' and has very minor side-effects,.
The import, sale, and manufacture of medicinal plants and
OTC drugs are regulated by the Pharmaceutical Affairs Law (Law No.
145 of August 10, 1950 Amendments Law No. 161, Sept. 15, 1962 No
135, July 12, 1963 No. 151, June 25, 1969 No. 37, June 13, 1975
and No. 56, Oct. 1, 1979). In addition, a number of other
regulations, including the Food Sanitation Law, Plant Quarantine
Law, Poisonous and Deleterious Substance Control Law, Narcotic
Control Law, Cannabis Control Law, and Law of Opium, have to be
observed.
The Ministry of Health and Welfare has approved some 200
kinds of medicinal plants and listed them in the Pharmacopoeia of
Japan. Another 59 items are classified as not listed in the
Pharmacopoeia but are treated the same as those listed. For
medicinal plants falling under this regulation, a simplified
description is acceptable for importation. The properties and
quality of these materials are specified in the Pharmacopoeia of
Japan. Medicinal plants may bu imported under the classification
of 'medicinal supplies' or 'materials for other purposes' such as
food additives. When medicinal plants are imported to Japan as
medicinal supplies, they must meet the requirements of the
Pharmacopoeia or else, they cdlnnot pass customs.
Concerning medicinal pl1ints other than those listed in the
Pharmacopoeia of Japan, the Asiuoc.iations of herb dealers in Japan
have cooperated in making uniform regulations and such items are
authorized by the Ministry of-Health and Welfare.
Exact details on the certification procedures are not
available to this study, except that the Hong Kong Chinese Medicine
Merchants Association Ltd. has been issuing letters to its members
39
to confirm the identity of medicinal herbs due for shipment to
Japan (Appendix 2). Nevertheless, the Japan External Trade
Organization emphasized that the Japanese industry wants from the
overseas exporters improvement in the quality of medicinal plants,
elimination of foreign substances, and improvement of packing.
They expect suppliers to watch the goods against moisture, mold,
rats and vermin, since recently, surveillance by the authorities
concerned has become more severe.
For OTC drugs, the Ministry of Health and Welfare has also
selected 210 Chinese medicine formulations and recognized them as
suitable for medical uses. Specific ratios of the constituents of
medicinal plants in each formulation are also stipulated.
Importation of OTC preparations using those formulations accepted
in the Pharmacopoeia of Japan needs no special approval, except
those required by the Customs for quality surveillance and tariff.
For Chinese OTC drugs not specified in the guideline are
individually evaluated for efficacy and safety on the base of data
from clinical reports and other sources. Concerning customs
clearance of medicine to be imported, a certification of the
medicine is required. For that purpose, agents of the Ministry of
Health and Welfare are stationed at Kobe Port and Osaka
International Airport.
Some form of certification is definitely required by Japan.
However, apparently, the requirements for Chinese medicines from
Hong Kong are not too demanding at the moment, as evidenced by the
letters of confirmation of identity issued by the Hong Kong Chinese
Medicine Merchants Association Ltd. (Appendix 2).
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H) Netherlands
The Netherlands is an important buyer of Chinese medicines
from Hong Kong. In'1983, the Netherlands imported from Hong Kong
$5,587 of Chrysanthemum, $2,802 of Ginseng, $7,700 of Birds nest,
$188,480 of Seeds of Anise and other species, $2,655 of Pepper and
Pimento, $38,322 of Plants for Perfume and Pharmacy, and $1,377,01
of OTC drugs.
In response to our enquiry, Ms. Juliette A. Strijkers,
Vice-Consul in charge of the Consulate-General of the Netherlands
here, contacted the Netherlandi3 Ministry of Welfare, Public Health
and Culture, and found out from there that the import of Chinese
herb medicines into the Netherlands is not controlled by any
special regulation in force. However, as with any medicinal or
pharmaceutical product, a permit from the Ministry is required for
the permission to import and sell the product in the Netherlands.
Each product will be reviewed separately. The exact details and
practice are not clear to us al. the time we are preparing this
report
I) New Zealand
New Zealand is only a very minor buyer of traditional
Chinese medicine exported and/or re-exported from Hong Kong. In
1983, New Zealand imported $53,824 of OTC drugs, $155,370 of Plants
for Perfume and Pharmacy, and $5,677 of Thyme and other spices, and
$824 of medicated Chinese wines. However, New Zealand appears to
be very alert to the importation of Chinese medicines. Several
times in the past four years, items were withheld at the Customs in
New Zealand the representatives of the Commissioner's office of
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New Zealand in Hong Kong would then contact the Chinese Medicinal
Material Research Centre of Thu Chinese University of Hong Kong and
other agencies for information and assistance in identifying the
items. A recent request went to the Food Drug Administration of
the USA on a sample of marijuana seeds exported from Hong Kong.
The marijuana seeds are often used in Chinese medicine as a mild
laxative under the herb name Huo-Ma-Yen
As from December 1962, New Zealand has a system whereby no
person may legally distribute, advertise or sell any medicine prior
to obtaining consent to do so, and from 1970 that has meant the
consent of 'the Minister of Health. The Medicine Act 1981, gazetted
in 1984, gives the Department of Health authority to withhold
medicines addressed to private individuals where these are found to
contain substances classified under the Regulation as prescription
medicines. However, Chinese medicines are excluded from this
Regulation because the Medicines Regulations 1984 specified that
Nothing in subclause (3) of this Regulation shall apply to a
remedy that is, and is described as, homoeopathic, except when
they contain scheduled ingredients.
As long as they do not bear any claim of therapeutic value,
Chinese medicines may be imported as food and spice, and thus
accordingly will be controlled by the Food Act of New Zealand.
Regretfully, the Food Act has not been gazetted yet, and thus is
not available to this study.
Anyway, we can still say that New Zealand would welcome and
may demand certification services for all Chinese medicines due for
shipment to New Zealand, simply by judging the practice of its
Customs office as well as the comment made by the Director of the
Department of Health in New Zealand in response to our enquiry--
（ 火 麻 仁 ）
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"Notwithstanding the fact that the general availability and usage
of Chinese medicines within New Zealand is fairly limited, it would
nevertheless be a great help to this Department if we had access to
the type of information you propose collecting, etc., in dealing
with many of these (Chinese medicines) as they are intercepted by
officers of our Customs Department, upon arrival in this country.
J) Norway
Norway is a very minor buyer of the Chinese medicines
exported and/or re-exported from Hong Kong. In 1983, Norway took
from Hong Kong only $10,006 worth of OTC drugs.
In Norway, drugs marketed in packages designed for the
individual consumer are regarded as pharmaceutical specialities.
Regulations concerning pharmaceutical specialities were issued by
the Ministry of Social Affairs on June 1, 1979 pursuant to the
Medicinal Goods and Poisons Act dated June 20, 1964. According to
the Regulations, approval is needed for medicines however, an
exemption from approval is provided to Homeopathic preparations for
which a prescription is not required. Nevertheless, even if
exempted, anyone manufacturing, importing, selling or delivering
products which are exempted pursuant to sub-section 1 of the
Regulations, must on request, supply the National Centre for
Medicinal Products Control (Statens legmemiddelkontroll) with
'_nformation concerning the types and extent of this activity. The
Ministry may issue more detailed conditions and regulations for the
manufacture, import, sale and delivery of products included in
sub-section 1, and may decide that approval is nevertheless
required for certain products of this type.
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Apparently, there is little need for certification services
for traditional medicines, if we rely only on this Regulation. It
should be cautioned that herbs as spice and food are regulated by
regulations on Foods, and may have to meet a different set of
requirements, which requirements are regretfully not available to
this study.
K) Singapore
Singapore is a major buyer of Chinese medicines from Hong
Kong. In 1983, Singapore absorbed from Hong Kong the following
amount of Chinese medicines: Liquorice roots $552,784, Angelica
$6,330,838, Codonopsis $1,305,570, Astragalus $3,492,413, Dioscorea
$72,747, Rehmannia $500,161, Chrysanthemum $3,455,848, Boxthorn
fruit $2,570,001, Ginseng $69,056,344, Sandlewood $6,812, Shell
Mollusc $12,220, Birds nest $282,015, Ginger dried $1,173,945,
Saffron $320,512, Thyme and other spices $64,572,452, Seeds of
Anise and other species $5,260,055, Cinnamon $76,784,099, Pepper
and Pimento $217,742, Plants for Perfume and Pharmacy $106,952,103,
OTC drugs $39,067,867, and Chinese medicinal wines $996,069.
According to Ms. Amy Lim of the Inspectorate Section,
Ministry of Health, Singapore, who was on a business trip to visit
the local Department of Health, told us that there is no control on
traditional medicines, whether Chinese, Indian or Malay, as long as
they do not contain schedules posions and excessive amount of heavy
m:-tals. Indeed, she commented that Singapore has a system very
similar to that of Hong Kong, since both are related to the British
system for historic reasons. No certification is required under
the law for-the-import of Chinese medicines. However, the
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Inspectorate Section keeps close surveillence on such products. In
the last few years, a number of OTC Chinese drugs containing
excessive amount of heavy metals were rejected from importation.
Recently, a shipment of Angelica root containing excessive amounts
of pesticides was also rejected.
I.) Sweden
Sweden is only a minor buyer of our exports and re-exports
of Chinese medicines. In 1983, it absorbed directly from Hong Kong
the following items: Chrysanthemum $1,980, Thyme and other spices
$3,660, Seeds of Anise and other species $120,393, and OTC drugs
$48,204.
Drugs and pharmaceuticals in Sweden are covered by the
Pharmaceutical Act (Dec. 7, 1977) and supervised under the National
Social Welfare Board. An exemption was inserted on Jan. 1, 1978 in
caction 1 paragraph 3 of the Pharmaceutical Act (1962:70, changed
1977:570), saying that the provision of this Act shall, unless the
Board decides otherwise, not b„ applied as regard to.... such drug
that from satisfactory experience at normal use does not involve
sanitary risks for a person on an animal and in which drug the
active component is a part of a plant or an animal, a mineral or a
bacterium cultivation, salt or salt solution in the nature. Thus,
OTC medicines (called naturopathic medicines) are exempted from the
stipulations in the Act. However, before an OTC drug is available
to the consumer according to the exemption, the manufacturer,
importer or the person who sells the product in the first place
shall report to the Board.
The report submitted to the Board will normally not lead to
an actual examination by the Board but the aim will be to judge in
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general the reliability of the statements submitted. No special
documentation about the effect of the drug is needed but the
reasons for the judgement that the drug does not involve sanitary
risks at normal use has to be carefully explained. It is importan
to state in the report the complete composition with indication of
the kind and quantity of each component. Each component has to be
indicated by a common Swedish name, or in the absence of which, the
Latin, German or English name. As for plants and parts of plants,
however, the Latin name of the mother plant shall always be stated,
Responsibility for the drug not involving sanitary risks fox
a person or an animal lies upon the manufacturer or importer of the
drug. The duty of the Board is merely to investigate whether the
reporter's motivation for the harmlessness of the drug at normal
use corresponds to traditional and/or scientific acceptance. -No
approval of the reporter's judgement will be granted by the Board.
To support the manufacturer/importer's judgement that the
drug at normal use would not involve sanitary risks, proper
documentation is suggested. Such documentation may consist of
references to scientific literature or statement about one's own or
other persons' examination of good scientific quality. The
emphasis is on supports from current scientific publications,
manuals or other scientific documents for each active component.
Similarly, marketing of the OTC drugs is subject to the
regulations of the Marketing Law (1975:1418), for which the
National Board for Consumer Policies (Konsumentverket/KO) is the
administrative authority. This Board issued another set of
guidelines. The exemption as provided in the Pharmaceutical Act is
also accepted. However, it stipulates that when marketing a
naturopathic drug there may not, either with text or with a picture
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or verbally, be any indication or suggestion that the drug is
effective against any disease or symptoms of disease, which for
r?iagnosis or treatment requires a contact with a physician or that
the drug may or should be used at such state. In the Guidelines,a
list of approvable uses and claims, such as flatulence and
menstrual pains, and another list of non-approvable uses and
claims, such as asthma, impotence, and cancer, are given. Moreover
such products should be labelled with a statement that the drug has
not been subject to any control stipulated for drugs.
Both regulations emphasize the need of scientific support.
However, no stipulation is specified for the authentication and
quality control of the drugs. Under this situation, dealers of
herbs and traders and manufacturers of OTC drugs are paying little
attention to the need of authentication and quality control. The i
most relevant issue is the availability of scientific
documentations which would hell) them clear the National Social
Welfare Board. Two of our informants, both in the OTC drug
1usiness, kept repeating that they are more interested in better
documentation to support their applications. They are very
interested in accessing to the computer databank on Chinese
medicines established in the Chinese Medicinal Material Research
Centre of The Chinese University of Hong Kong. One of them added
that the service to certify crude and OTC medicines would certainly
be of interest to importers, but there is no government rule for
such services.
M) Switzerland
Switzerland imported very little Chinese medicine from Hong
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Xong. In 1983, it accepted only the following amounts of
materials: Ginseng $39,960, Birds Nest $6,500, Seeds of Anise and
other species $93,459, and OTC drugs $169,979.
There is no general regulation on traditional medicines,
herbs, and spices in Switzerland. However, OTC drugs from plant
origin brought on the market in Switzerland as manufactured and/or
finished products have to be submitted for registration at the
International Office for the Control of Medicaments (IOCM)
according to Article 13 of the Regulation for the Implementation of
the International Convention on the Control of Medicaments, such
materials shall be analysed by the IOCM Laboratory to verify their
composition and quality by chemical, physico-chemical, and if
necessary morphological or microbiological methods, etc. If the
laboratory of the IOCM is unable to perform the necessary tests
(e.g. if biological or technical tests are needed), the IOCM may
require the applicant to submit a report of analyses from an
institute recognized by the IOCM or may directly commission such an
institute to carry out these tests at the expense of the applicant.
As is evident from the above-mentioned regulation, the IOCM
of Switzerland may require certification and testing services on
OTC Chinese medicines bearing indications of therapeutic value.
N) United Kingdom
The 1983 Hong Kong Trade Statistics shows that U.K. is only
a minor trade partner when traditional medicines are concerned. In
1983, U.K. imported only the following items from Hong Kong:
Liquorice root ($1,750), Angelica ($9,000), Codonopsis ($3,600),
Dioscorea ($1,800), Rehmannia (1,000), Chrysanthemum ($58,815),
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Ginseng ($3,600), Brids nest ($40,290), Ginger dried ($14,872),
Thyme and other spices ($394,995), Seeds of Anise and related
species ($107,820), Cinnamon ($102,000), Pepper Pimento
($2,821,795), Plants for Perfume and Pharmacy ($806,498), and OTC
drugs ($237,821).
The manufacture, sale and supply of all medicines in the
United Kingdom comes under the strict control of the Medicines Act
of 1968. However, herbal remedies are exempted from certain
provisions of the Act, including licensing requirements (Section
12.1) and restriction to pharmacies (Section 56). As a result,
herbal remedies are available to the public from medical
practitioners, pharmacists, medical herbalists and retail
shopkeepers. The latter source is the main one for the supply of
such remedies. As long as the materials in the prepacked herbal
medicines are not restricted to pharmacies by the Medicines Act or
by the Medicine (Retail Sale and Supply of Herbal Remedies) Order
1977, such herbal remedies are freely circulated. Under the latter
Order, some 35 potent plants, ijuch as Areca catechu, Dryopteris
filix-mas, Viscum album, and Strophanthus, which are listed in Part
I of the Order, were brought wider Pharmaceutical control. In
addition, a further 40 plants, included in Parts II and III, can be
supplied within certain specified limits by herbalists. Included
among those 40 plants are aconitum, atropa, cinchona, colchicum,
conium, convallaria, datura, ephedra, gelsemium, hyoscyamus,
lobelia, pilocarpus, and senecio. Only thirteen plant drugs are
defined as prescription only medicines and these are belladonna,
conium, croton seeds, digitalis, gelsemium, ignatius bean,
jaborandi, nux vomica, podophyllum, poppy capsules, rauwolfia,
sabadilla and veratrum. In addition, the Food Additives Committee
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includes 572 herbs on its list (Phillipson 1981).
Herbs and OTC drugs outiiide of the lists are freely imported
without any special form of certification, except maybe a
phytosanitary permit.
0) USA
The United States of America is a big trading partner with
Hong Kong. In 1983, it took from Hong Kong the following worth of
Chinese medicines: $150,303 of Licorice root, $715,667 of Angelica,
$517,091 of Codonopsis, $678,071 of Astragalus, $803,574 of
Dioscorea, $103,269 of Rehmannia, $362,602 of Chrysanthemum,
$1,004,440 of Boxthorn fruit, $11,183,637 of Ginseng, $43,218 of
Sandlewood, $2,152,233 of Birds nest, $13,276 of Cloves, $279,365
of dried ginger, $2,431,474 of Thyme and other spices, $4,180,216
of Seeds of Anise and other species, $2,154,321 of Cinnamon,
$1,650,289 of Pepper and Pimento, $43,267,289 of Plants for Perfume
and Pharmacy, $13,200,103 of OTC drugs, and $284,230 of Chinese
medicinal wines.
Traditional Chinese medicine, whether presented in the form
of medicine, food, or spice, is under the jurisdiction of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301-392), which is
the most extensive law of its kind in the world. Many of the
States in the U.S. have laws similar to the Federal Law, and some
have provisions to add automatically any new Federal requirements.
This Act prohibits distribution in the U.S. or importation of
articles that are adulterated or misbranded, to avoid the consumers
from defective, unsafe, filthy and deceptive (misleading or false
claims) materials intended for use by man and animals.
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Imported items regulated by the FDA are subject to
inspection by the U.S. Customs at the time of entry. Shipments
found not to comply with the laws and regulations are subject to
detention, so that the items are brought into compliance,
destroyed, or re-exported.
There are a number of relevant regulations that have direct
impact on the importation of traditional Chinese medicines:
a) the FDA Current Good Manufacturing Practice Regulations, which
set standards of sanitation, inspection of materials and
finished products, and other quality controls
b) the FDA Food Standards, which set specification for many foods=
c) Safe tolerances set by the Environmental Protection Agency on
residues of pesticide chemicals in food comodities
d) Fair Packaging and Labelling Act, on information to be
presented in the labels of nonprescription (OTC) drugs:
e) Plant Quarantine Act of the U.S. Department of Agriculture,
which may require import permits for crude plant materials
and
f) Convention on International Trade in Endangered Species of Wild
Fauna and Flora, effective on may 23, 1977, which prohibits
tradings of or requires permits or certifications origin.
This applies to wild ginseng, rhino horns, ivory and
other products of animals and plants included in the list.
With appropriate arrangement, the FDA may relieve its burden
of inspection by allowing certain industries and associations to
discipline their products and-imports. The American Spice Trade
Association (ASTA) is a good example. In 1967, 75% of all imports
of spices arrived through the Port of New York, and the amount of
imports kept increasing at the rate of 5% annually. The FDA
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Regional Office at N.Y was swamped with samples for inspection
(4,000 samples a year in 1967). As a result, an agreement was
reached between the FDA and the ASTA for the FDA to give the spice
industry the 'privilege' of importing spices without formal FDA
inspection. In exchange for this 'privilege', spice importers
would guarantee that spice shipments are to be sampled for
',acroscopic analysis by an ASTA approved laboratory, and, if found
adulterated, are to be returned to the exporting country or to be
properly cleaned or reconditioned before being put into consumer
channels. Thus, the ASTA came up in June 1969 (later revised in
1971, 1975, and 1982) the ASTA Cleanliness Specifications for
Unprocessed Spices, Seeds, and Herbs (Foreign and Domestically
Processed), which dictates a set of standards and testing methods
mutually accepted by the ASTA and FDA. All spices (including many
crude Chinese medicines) could clear the Customs offices if
certified to have met the standards by approved laboratories.
We are not sure if a foreign laboratory can be approved by
the ASTA or the FDA at this moment. Contacts with the ASTA for
information on whether oversea:u suppliers can rely on the
certification and testing results of laboratories in the importing
countries did not receive any reply yet. However, two pieces of
..nf ormation showed that the FDA and the U.S. Customs Service may be
required by law to employ cert:lCication services from the U.S.A.
In the first place, it was specifically indicated that at least
samples of color additives and insulin drugs must be tested and
certified by FDA laboratories,. Certification of a color by an
official agency of a foreign country cannot, under the provisions
of the law,. be accepted as a substitute for certification by the
FDA (HHS Publication No. (FDA) 85-1115). In the second place, Mr.
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Robert Slomovitz, Chief, Commercial Operations, Branch 2, of the
U.S. Customs Services (New York Seaport) replied that the U.S.
Customs Service is governed by the use of a product in the United
States. His choice of the word 'product' left us confused whether
he actually may have meant service, particularly certification
services. No matter what stance the U.S. is taking, we believe
t1iat the FDA and U.S. Customs Services could be convinced to accept
reliable certification serviced offered in foreign countries, when
they are over-whelmed by the increasing amounts of Chinese
medicines importing to the U.S. as in the case with the ASTA. When
the time is mature, some bilat«ral arrangement can be negotiated.
Summary
To summarise we can draw the following conclusions
concerning the regulations and needs for certification on
traditional medicines:
A) All of the countries reviewed do have some provisions to give
exemptions from the need of pharmaceutical approval to
traditional medicines. However, there are different
practices. Strictly no control is lavished on Chinese
medicines in Singapore provided that they do not contain
scheduled poisons the OTC drugs there can make therapeutic
claims. In most other countries, no special approval is needed
for traditional medicines, as long as they do not bear any
indication of therapeutic value. In a few countries, such as
Australia, France and Japan, the authorities have short-listed
a number of plants that are considered safe with mild
therapeutic effects remedies derived from those plants on the
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lists do not have to go through strict examination and approvei
procedures. The USA have tough laws that cover drugs, foods
and cosmetics. Herbal remedies, unless already in use before
1958, are regulated by either the drug or the food
regulations. If the remedy makes any therapeutic claims, it is
governed by the regulations on drugs. If it claims no
therapeutic value, it is still covered by the regulations on
foods.
The regulations and requirements among the fifteen
countries sampled are so variable that we could not identify a
meaningful pattern and provide a reasonable rationale. It is
fair to say that the cultural background and state of
technology are probably a factor. For example, France and
Germany have a long history of using herbal remedies and the
habit continues even when modern medicaments are readily
available. In these two countries, the importers themselves
would prefer certification as to the identity, quality and
purity of herbal remedies. Japan has its version of Chinese
medicine, and it shortlisted a fixed number of crude and OTC
drugs to simplify the chor€n in control. This approach has
been followed by Australia. Among the developing countries,
Indonesia has a set of strict regulations however, our
understanding is that enforcement of such regulations is
lagging behind. Singapore, like Hong Kong, has been placed
under the sovereignty of the British Empire, and no regulation
on traditional medicines is established. The rationale is to
avoid conflicts with the traditional practice of the people.
The lack, of technology in controlling traditional medicines is
probably the actual reasons behind this lack of any
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regulation. Moreover, the state of awareness and political
strength of the herbal industry may help shape the
regulations. Indeed, the historical development of such
regulations would be an interesting subject for insights into
the variations of these reijulations among the countries
surveyed.
B1 Some form of certification on the identity, quality, and
pesticide levels are needed for the following countries:
Australia Plants other than caulinary herbs
China mainland OTC drugs
Taiwan OTC drugs
France French importers perfer certificate of
analysis
Germany German importers prefer certificate of
analysis
Indonesia OTC drugs
Italy No Italian importers may find certi-
fication of identity and quality
valuable
Japan Yes
Netherlands Not clear, probably not
New Zealand Customs would prefer certification
Probably notNorway
NoSingapore
No, but emphasis on scientificSweden
documentation on safety and efficacy
OTC drugs if claiming therapeutic valueSwitzerland




Even though quite a number of countries appear to need
certifications for traditional medicines, we are not sure if
they actually demand it. The style of administering and
enforcing the laws and regulations can be very different from
the black-and-white writings. For example, Singapore has no
legal control over Chinese medicines however, its Drug
Inspection unit under the Ministry of Health constantly checks
the amount of heavy metals in imported Chinese medicines. As a
result, to meet Singapore's standards, manufacturers here have
to make special efforts to have the heavy metals checked by
certification laboratories. On the other hand, countries with
apparently strict requirements may not be really consistent
with their administration. Further research work is
necessary. Nevertheless, it is fair to conclude that
certification on the identity, quality and pesticide level are




DEMAND FOR TESTING AND CERTIFICATION SERVICES
(III) LOCAL AND F(112EIGN GOVERNMENT AGENCIES
A) Local Government Agencies
A structured questionnaire (Questionnare B, Appendix 4) was
sent to thirteen selected individuals in key positions in various
lepartments of the Hong Kong Government, including those that deal
with consumer protection, customs, pharmaceutical control,
nedicines and health, industry, crimes, agriculture, analysis, and
legislature and urban services. Only seven questionnaires were
returned. Another respondent replied by a letter instead of the
juestionnaire with the comment that his unit rarely has reason to
teal with Chinese medicines. We count this eighth response as one
response with all negative answers (except in question e), and thus
)ur response rate was up to 62%.
The responses of the eight government officials are
summarised in Tables 6.1 to 6.4.
Although the sample used is rather small, it covered all the
r-levant departments which may possibly have to handle Chinese
nedicines. Moreover, the persons selected are in key positions and
-.over both operational and administrative areas. Their opinions
are very significant, although not necessarily representating the
views of the corresponding departments.
From Table 6.1, it can be seen that a fair number of
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government departments have to deal with the testing and
certification of Chinese medicines (38-50%).
However, as shown in Table 6.2, only a few suggested a
dependable source of such services (0-38%). The government is
particularly weak in authenticating the species of both crude and
OTC drugs, since 50% of the respondants need some form of
authentication while none of them know of any dependable source fol
the service. Apparently, many of the departments/units in need of
testing services have no access to a testing source. One
respondent suggested the Institute of Pathology of the Medical and
Health Department and a few pointed to the Government Laboratory,
for some of the testings needed. The Hong Kong Chinese Medicine
Merchants Association Ltd. is suggested by one respondent for
organoleptic identification. Another respondent indicates that the
Hong Kong Standard and Testing Centre can check heavy metals. The
capability of these units in handling such technicalities and in
servicing the needs has to be confirmed and evaluated. At the
moment, we feel that it is fair to say the number of respondents
who know of a dependable source of service is lower than the number
in need of such services.
Because of the small sample size, we cannot say whether
there is any significant increase in demand for testing and
certification services for Chiriese medicines in the future as
compared to the current situation as predicted by the government
respondents, although a few percentages are slightly higher in
terms of future needs (Table 6.3).
All the seven respondents who returned the questionnaire
agreed unanimously that Hong Kong should have stricter regulations
on Chinese medicines (Table 6.4) the eighth respondent did not
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comment on this question, and we cannot infer a yes or no, which
makes it necessary for us to discard him in question e. If the
policy-makers rely on the opinions of this group of officers who
may deal with Chinese medicines in one way or another, laws and
regulations on Chinese medicines will be much stricter, thereby
increasing the demand for testing and certification services for
Chinese meicineq_
B) Foreign Government Agencies
A number of foreign government agencies made comments on the
need of testing and certification services.
Their comments are aunt-oi hclnw
I) Favoring A Source of Testing/Certification
Services on Chinese Medicines
1) Australia
Commonwealth Department of Health, Assistant Secretary of
the Therapeutic Goods branch: Recently there has been an
increase in interest in Chinese medicine in Australia
coinciding with the arrival from South-East Asia of immigrants
and refugees, many of whom wish to import and market both crude
herbs and OTC preparations. In many instances authentication
of crude drugs has been impossible and claims made for
formulated products are considered unrealistic in the absence
of supporting data. It is considered that such a service
(authentication and certification of Chinese medicine) may be




Department of Health, Director, Division of Clinical
Services: By way of initial comment, notwithstanding the fact
that the general availability and usage of Chinese medicines
within New Zealand is fairly limited, it would nevertheless be
a great help to this department if we had access to the type of
information you propose collecting, etc. in dealing with many
of these as they are intercepted by officers of our Customs
Department, upon arrival in this country.... They can surely be
nothing but good result from your establishing the Drug Control
and Certification Centre, if this provides a central
information source, which conceivably could be made available
in some way to other interested bodies.
3) Netherlands
Central Bureau Voor do Statistiek, Director: In view of
increasing interest in non western medicine, we believe that a
reference library on thin subject could constitute a
significasnt source of information and knowledge in this field.
4) Switzerland
Intercantonal Office for the Control of Medicaments,
Registration Office, P. Klitin: In our opinion, the service as
mentioned might be useful, as a certification system could
guarantee certain standardu which do not exist at the moment.
5) USA
Consultate-General of the USA, H.K., Consul-General:..,
While not familiar with the subject, the growing Chinese
population in the United States and the increasing interest by
Americans in natural foods and remedies suggest that there
would be some American interest in research findings on
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traditional Chinese medicines.
Department of The Treasury, U.S. Customs Service, N.Y.,
Chief of Commercial Operation: The Customs Service on
occassion has to determine the use of imported products.
However, we are governed by the use of a product in the United
States. We are unable to comment on whether or not other
governmental agencies or public companies would utilize your
type of service.
II) Not Favoring A Source of Testing/Certification
Services on Chinese Medicines
1) Switzerland
Consultate General of Switzerland, Hong kong,
Consul-General: Since there is rather limited demand for
Chinese medicine in Switzerland, there does not seem to be a
necessity for the creation of a special certification centre in
Hong Kong, at least not from my personal point of view.
Understandably, some countries would welcome the
establishment of a servicing centre for the authentication,
standardization and quality control of Chinese medicines. The
Swiss Consul-General is an exception he does not see any need
for such services. The Cuutoms Service of the USA said that
his Department has to rely on American service, although he
does not exclude the possibility that other departments and
agencies may use a foreign service.
61
TABLE 6.1
PERCENTAGES OF RESPONDENTS FROM HONG KONG GOVERNMENT
INDICTATING THAT THEIR DEPARTMENTS/UNITS NEED




1) Species authentication of crude drugs 50%
2) Species authentication of OTC drugs 50%
3) Organoleptic check 38%
4) Residue pesticides 38%
5) Heavy metals 50%
6) Qualitative test for bioactive components 50%
7) Quantitative test for bioactive components 38%
8) Micro-organisms and aflatoxins 38%




PERCENTAGES OF RESPONDENTS FROM HONG KONG GOVERNMENT
SHOWING KNOWLEDGE OF A DEPENDABLE SOURCE OF
TESTING SERVICES ON CHINESE MEDICINES
% of Affirmative Suggested Source
Services Responses of Services
1) Species authentication of 0%
crude drugs
2) Species authentication o%
of OTC drugs
3) Organoleptic check 13 (Hong Kong Chinese
Medicines Merchants
Association Ltd.)
25%4) Residue pesticides (Government laboratory)
5) Heavy metals 38% (Government labortory)
(HK Standard Testing
Centre)
6) Qualitative test for 13% (Government laboratory)
bioactive components
7) Quantitative test for 13% (Government laboratory)
bioactive components
8) Micro-organisms and aflatoxinu 13% (Institute of Pathology)
25%9) Foreign substances (Government laboratory)
13%101 Toxicity (Institute of Pathology)
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TABLE 6.3
PERCENTAGES OF RESPONDENTS FROM HONG KONG GOVERNMENT
INDICATING DEMANDS FOR TESTING/CERTIFICATION




1) Species authentication of crude drugs 50% 63%
2) Species authentication of UTC drugs 50% 63%
3) Organoleptic check 25% 25%
38%4) Residue pesticides 38%
5) Heavy metals 63% 63%
6) Qualitative test for bioactive components 25% 50%
7) Quantitative test for bioac-tive components 25% 50%
8) Micro-organisms and aflatoxins 25% 38%
9) Foreign substances 63% 63%
10) Toxicity 38% 50%
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TABLE 6.4
PERCENTAGES OF RESPONDENTS FROM HONG KONG GOVERNMENT SHOWING
THAT STRICTER REGULA'L'ION ON CHINESE MEDICINES







AVAILABILITY OF TESTING AND CERTIFICATION SERVICES
In order to determine if' testing and certification service
are available for Chinese mediclnes, we have prepared a structured
questionnaire (Questionnaire C, please refer to Appendix 5), and
sent it to local testing and certification laboratories. We use
the membership list of the Hone Kong Association of Certification
Laboratories as our guide. Moit of the members of that Association
specialise in textile and construction business. We could only
identify nine members, which either specified that they would
handle pharmaceuticals, foods, chemicals and water, or described
themselves with vague and broad capabilities that may cover Chinese
medicines. One more laboratory was selected, since it is a leading
laboratory in Hong Kong although it does not join the HKACL.
Six of the ten laboratories responded to our enquiry. Three
of the respondents simply replied that they do not provide any
service on Chinese medicines. We take their replies as negative
answers to questions A-F of Questionnaire C but discarded them
when calculating the percentages of responses in questions G and H.
since these questions demand a personal answer. Responses from the
local testing/certification laboratories reveal that the services
for testing and certifying Chinese medicines are rather limited and
incomprehensive (Table 7.1). The services offered are mainly those
that use the same techniques as for testing modern medicines. The
key tests concerning species authentication, bioactive components
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and toxicity are completely unavailable.
Only 1 respondent indicates that his laboratory will start
offering testings on residue pesticides for both crude and OTC
drugs in the next three years. This same respondent also forecasts
that the demand for services on crude and OTC Chinese medicines
will increase in the future. He favors stricter regulations on
Chinese medicines as well. It is noteworthy that majority of the
local testing/certification laboratories will be strategically
ill-prepared to face an upsurge for demands for services on Chinese
medicines, if there is any change in legislation.
This lack of interest in servicing Chinese medicines may be
caused by the low frequency of services needed by the local
dealers, manufacturers and agencies requests for such services
come only once per month (Table 7.2). The absence of any
regulation on Chinese medicines induces little incentive from the
local business sector to have their products tested and certified.
We are told in our interviews with representatives of the
testing/certification laboratories that at -least one OTC
manufacturer requests monthly tests on the amount of heavy metals
in his products. Among the government sector, the Consumer Council
is a frequent customer for test on Chinese medicines. However,
the limited tests provided by local laboratories could not possibly
satisfy the demands from this Council.
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TABLE 7.1
PERCENTAGES OF RESPONDENTS FROM LOCAL TESTING AND
CERTIFYING LABORA'T'ORIES OFFERING SERVICES
ON CHINESE MEDICINES
Offering for Offering for
Services Crude Drugs OTC Druou
1) Authentication of species 0% 0%
2) Organoleptic check 17% 17%
17%3) Residue pesticides 17%
4) Heavy metals 34% 34%
5) qualitative check of bioactive 0% 0%
components
6) Quantitative check of bioactive 0% 0%
components
7) Alflatoxins/microorganisms 0% 17%
8) Foreign substances 0% 0%
9) Toxicity 0% 0%
10) Nature of coating on tablet/pill NA 17%
11) Disintegration time of tablet/pill NA 17%
12) Weight variation of tablet/pill NA 17%
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TABLE 7.2
FREQUENCY OF PROVIDING TESTING/CERTIFICATION
SERVICES ON CHINESE MEDICINES
BY LOCAL LABORATORIES
Services on Services on
Frequency Crude Drugs OTC Drugs




CHINESE MEDICINAL MATERIAL RESEARCH CENTRE
THE CHINESE UNIVERSITY OF HONG KONG
The Chinese Medicinal Material Research Centre (hereafter a
CMMRC) is a research unit under the Institute of Science and
Technology of The Chinese University of Hong Kong. It follows the
mission of the University in promoting the integration of Chinese
and Western cultures by devoting to the study on Chinese
medicines. It aims to evaluate the true efficacy of traditional
Chinese medicines and to put thi:tm on a more scientific basis.'
CMMRC is a multidisciplinary research centre, consisting of
faculty members who are interested in the scientific investigation
of Chinese medicines from the Faculties of Science, Medicine,
Social Science, and other units (including library, computer
centre, etc.)
Programs conducted in the Centre can be graphically and





Figure 1. Graphic Presentation of the Programs of the CMMRC
The two lower triangles Lire the supporting pillars of the
research work of the CMMRC. Thuy represent the two key areas of
levotion undertaken by the Centre, namely, a unique computer
iatabase on Chinese medicines and a museum of Chinese medicines.
mne computer database started in 1980 with the generous support
from IBM which supplied both hardwares and softwares to the
Droject. One of the most significant donation from IBM is the loan
to the Centre the program STAIRtI, which is a very powerful and
versatile system for information retrieval and matching. The
iatabase stores information on Chinese medicines translated in
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English and MEDLINE terminologies. Hence, it is possible for the
Centre to link up this database with those of international
databases, such as Index Medicus, Biosis, and Chem Abstract, now
available through satellite in LOGHEED. It is continuously updated
with new translations and abstractions of relevant papers on
Chinese medicine published in Chinese. Hence, it is an important
bridge between the East and the West.
The Museum of Chinese Medicine collects, documents, and
conducts research on the authenticity, standardization, and quality
control of Chinese medicines. It is also open to the public by
Invitation and by prior arrangement. Currently, it is holding some
700 samples of crude Chinese medicines, donated by the local herb
dealers, particularly those of the Yee Yee Tong Chinese Medicine
Merchants Association Ltd. and of the Hong Kong Chinese Medicine
Merchants Association Ltd., anti by contacts in mainland China.
Each sample is identified and accompanied by data on its botany,
chemistry, pharmacology, and clinical data, stored in the computer
database. OTC drugs are gradually received from local
manufacturers and importers so far it is stocking some 50 items.
In addition, it also collects other artifacts, such as herbals,
utensils and machines used for the processing of Chinese medicines,
and needles employed in acupuncture. Research workers in the
Museum are compiling pharmacognostic profiles for the preparation
of a herbal pharmacopoeia for materials in Hong Kong and developing
accurate and specific tests for the identification of crude drugs
'with chemical fingerprinting.
The diamond sitting on top of the two supporting triangles
represents the research projects aiming at bioactivity and
bioactive components in Chinese medicines. Projects currently
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conducted include morning-after-pill from plants, male
contraceptives, abortifacient protiens, liver diseases,
cardiovascular malfunctions, ginseng, plant tissue culture, history
of herbals, and medical sociology. A small project on the
marketing and trading of medicinal plants has also been initiated.
The combination of computer database, museum, and
multidisciplinary investigation into important areas has made the
CMMRC a unique centre for the study of Chinese medicines. The-
results from this centre, as presented in publications, symposia,
new discoveries, and services in information and authentication of
Chinese medicines, have gained international recognition for the
CMMRC.
In terms of research facilities, the Centre has access to
all equipments available on campus. Some of the major equipments
include nuclear magnetic resonance spectrometers (60 MHz and 250
MHz superconducting FT PMR and CMR), high resolution mass
spectrometer, fully automated X-ray diffractometer,
ultra-centrifuges, high performance liquid chromatographs, liquid
scintillation, droplet-counter-current chromatographs, transmission
and scanning electron microscopes, generator for fast neutron
activation analysis, electron :spin resonance spectrometer, IBM 3031
main frame computers and PDP 11/70 minicomputer.
Baseline support is provided by the University, in the form
of faculty salaries, use of laboratory, library, computer
facilities, and administrative iervices, as well as overhead
expenses. Direct research assistants, materials and equipments,
however, are paid for mostly by outside grants and private
donations.. Some of the major grants:. and support come from
international agencies, includi.ng:..the World Health Organization,
73
United Nation Educational, Scientific and Cultural Organization,
International Foundation for Science, Ford Foundation, Commonwealth
Science Council, and Populations Council. A few projects are
contracted with various entities, such as the Consumer Council and
the New Zealand Deer Farmers Association. The Business sector has
also contributed to the financial strength of the CMMRC,
particularly those from IBM, Duw Chemical, and Vitasoy. Moreover,
a number of private donations, reaching HK$13 million, have been
received from the local foundations and philanthropists. With part
of the donations, the Centre has built two storreys in the Science
Centre East Block and a twelve unit residence for its research
workers. Two of the units of the residence building are reserved
for visiting scholars to the Centre. With this financial setup and
flexibility, the Centre is unique in the University. However, it's
survival and maintainence in the competitive world of research has
to rely on continuous input of fundings from outside agencies and
donors. A possible strategy for revenues for the Centre is to
provide services to the public for a fee or through the arrangement
of an endowment fund or government contract. Management of the
Centre has considered this option and feels that the Museum can
undertake some revenue-generating activities, such as the
authentication, standardization, and quality control of Chinese
medicines.
Strength of the Centre in offering services for the
authentication, standardization, and quality control of Chinese
medicines include the followings:
1) It has already stocked in hand some 700 voucher samples of
crude medicines which can be used as reference standards.
2) It has experience and already made progress in developing
74
standards, and teting protocols for the services.
3) It has close contacts with the herbal industry in Hong Kong.
4) It has close contacts with the government agencies in Hong
Kong.
5) It has close contacts with Chinese authorities and experts. Th(
Director of National Institute for the Control of Pharmaceutical
and Biological Products of the Ministry of Health, PRC, is one
of the three honorary advisors of the Museum of Chinese
Medicine. This unit is equivalent to the Food and Drug Adminis-
tration of the USA.
6) It has a computer database as a support.
7) Equipment-wise, it is very sophisticated.
8) Its management agrees that such services should be available to
the public, and that the Centre is willing to offer such
services. Indeed, the management agrees that the recognition
and social value of such services are equally important as
revenues generated from charges.
9) The University is a non-profit organization. It does not have
to rely on service charges for its existence. Rather, it can
be a very independent entity, suitable for its function as an
arbitrator in authentication, standardization and quality
control of Chinese medicines.
10) It has access to a pool of expertise available in the faculties
in the University.
11) It can be an extermely cost-effective unit to contract with the
Hong Kong Government for such sevices, especially in the
current transitional period when the Government would like to
gain such services without any major investment.
The Centre has its weakness too, particularly with
75
manpower. Most faculty memberu participating in the Centre are
supported by the University mainly for teaching, and they only
conduct research on a part-time: basis. More dedicated personnel ib
necessary. A few more assistants of at least matriculation level
are to be recruited and then trained for the routine testings. OnE
to two analytic chemists or pharmacists should be added to the
Centre to undertake more specialized testings and to supervise the
routine chores. It is hoped that these chemists and pharmacists
would be interested in developing new techniques and standards as
well as in participating in thu research programmes of the Museum.
To attract and maintain these persons, it is necessary to have a
substantial endowment fund or a long-term contract from the
government or funding agencies. Our-interviews with two of the
major testing laboratories gave us the impression that some of the
laboratories cannot break-even if they have to cover their rents at
market value and all depreciation costs. Moreover, the meager
demand for such services at the present moment, and probably in the
early phase of such a testing/certification centre, is not
sufficient to generate enough revenues to cover the payrolls of
these staff members.
Additionally, the Centre should substantially increase its
collections of standard samples of both crude and OTC drugs
available in Hong Kong. It would be an advantage if the Centre
should expand its scope of collection to include some of the common
items and their adulterants known in China and Southeast Asia
these samples would be very.helpful in view of the constant influx
of materials into Hong Kong from these regions. Finally, additions
of some automated equipments for routine testings and reference




Chinese medicines have been a stable source of health-care
for people in Hong Kong and other places where Chinese culture has
a strong influence. Just in Hong Kong alone, about HK$1,400
million's worth of Chinese medicines were imported in each of the
last few years, and about half of the imports were re-exported.
The trade volume helps to indicate the extensive amount of Chinese
medicines used locally and demanded abroad.
However, a major weakness of Chinese medicines is the lack
of standardization and quality control. This problem is
intensified by the absence of any regulation and control on these
medicaments by the local government. The loopholes have resulted
in misuses and abuses, including adulterations, substitutions,
erroneous application, inappropriate handling and storage, and
other inconsistence in quality. These misuses and abuses often
reduce the therapeutic value of these medicaments and in turn delay
recovery. In severe cases, the adulterated, substituted, and/or
mishandled materials may aggrevate the ailments and even prove
fatal. In the short-run, this problem is a matter of life and
death to the individual consumers. In the long-run, it reduces
productivity and hinders economic progress. Moreover, this
weakness may reduce the confidence of consumers in Chinese
medicines or even become an ob:itacle for its acceptability in
western markets.
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In this study, a fair percentage of the respondents from the
herbal industry indicated that they are seeking testing and
certification services for their products. Some of the tests, such
as the amount of heavy metals, are conducted to meet the standards
of drug inspection departments here and abroad. Some other tests,
such as the total content of active ingredients, are needed to help
them evaluate the quality of raw materials to be purchased and
promote their products in the market. A few also would like to,
gave tests on efficacy and toxicity, which are important for them
in promoting a drug and in satisfying foreign customs and
drug-control agencies. The retiults of Questionnaire A (Appendix 3)
show that there is a weak demand for such services from the local
herbal industry. As described by one of the respondents, the
incentive to pay for such services is rather low, since there is no
such requirement from the government. Another respondent disclosed
that he gambles by exporting his products to certain countries
without any prior testing, with the hope that his consignments may
not be intercepted and inspected. Nevertheless, over half of the
respondents believe that many of the testing and certifying
services mentioned in the Questionnaire A would be needed for them
to expand their markets and penetrate into new markets. Sixty-two
percent of the respondents expressed dis-satisfaction with the
services of local testing and certifying laboratories.
Although there is no regulation on Chinese medicines,
several government departments have to deal with these medicines.
Respondents (38-50%) from these departments revealed that they need
a dependable source of services for the authentication,
standardization and quality control of Chinese medicines. However,
most of them also disclosed that they do not have access to such
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sources of services. The Government Laboratory is mentioned in a
number of responses as a source of'service. However, our
interviews with members of the Laboratory show that their capacity
and capability in Chinese medicines are very limited. Our persona]
impression is that the Labortory may be able to handle a small
percentage of the services, frequently with the assistance from
faculty members of the Universities and Polytechnic. For example,
the Consumer Council has turned to and contracted with a member-of
the Chinese Medicinal Material Research Centre for the testing of
ginsenosides in instant ginseng teas available in Hong Kong. Most
of the government respondents believe that the demand for such
services will increase in the future. It is a regret that our
Questionnaire did not ask them for their rationale in this
forecast. Anyway, we did ask them whether Hong Kong should have
stricter control on Chinese medicines. Surprisingly, irrespective
of whether or not their respective departments need such services,
all of the respondents unanimouuly vote for stricter control. If
this preference for stricter control is representative of the
general consensus of the policy-makers, regulation on Chinese
medicines is likely to be established and, as an immediate
consequence, the demand for testing and certification services on
Chinese medicines is bound to niitltiply. Indeed, the Basic Law to
be drafted may make stricter control on Chinese medicines a
necessity, if it matches article 21 of the Constitution of the
People's Republic of China.
Regulations on traditional medicines in the countries
surveyed in this study are quite variable. The approaches to the
problem of. authentication, standardization and safety control
differ among these countries. Some of them, such as Singapore,
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are similar to Hong Kong and have no control on traditional
rzdicines. A few countries have short-listed a number of plants
that are known to have mild therapeutic value and no toxicity, and
allow them to enter the countries without rigorous testing and
approval. Generally, herbs and health foods bearing no indication
of therapeutic values can gain entrance into most countries quite
easily. Sweden, for example, even gives permission to print on the
labels of OTC drugs some minor symptoms, such as flatulence and
irregular menses. The Food and Drug Administration of the U.S.A.
tends to be very tough on traditional medicines. Overall speaking,
each country has its own regulations and special requirements, and
exporters to these countries have to handle them individually. Our
results show that at least half of the countries studied either are
requiring or would prefer to have some form of testing and
certification on the medicinal materials to be imported. Many of
the foreign agencies contacted in this study also expressed
Interest in and concern for the need of authentication,
standardization and quality control of traditional medicines, and
welcome the establishment of a testing and certification centre on
Chinese medicines.
Most of the testing and certifying laboratories replied to
our Questionnaire that they do not offer any service on Chinese
medicines. The few ones that do, indicate that their services are
not comprehensive, covering mainly tests on heavy metals,
pesticides, and physical property of such commodities. They also
revealed that the current demand for such services are rather
limited. During our interviews, members of a few testing centres
emphasized that testing technology for Chinese medicines is not
well developed and not readily uvailable. This problem may be part
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of the reason that the government hesitates to regulate Chinese
medicines.
Our review on the Chinese Medicinal Material Research Centre
of The Chinese University of Hong Kong finds the Centre quite
suitable for offering such services. It is well equipped and
experienced in testing Chinese medicines. The specimens in the
Museum of Chinese Medicine in the Centre can serve as standards for
comparison, while the computer database on Chinese medicines can
provide information and supporting documents on the properties of
the individual plants. Moreover, being a unit in a non-profit
organization, the Centre can serve as an independent arbitrator on
the authentication, standardization, and quality control of Chinese
medicines. The revenues generated from charge for such services
may not be sufficient to cover the expenses of the Centre, at leant
during the early phase when thou market is not mature enough and the
demands for such services are not high enough. However, the
services offered will benefit all people who use Chinse medicines,
and the technology developed will be much valued as a means to
raise the standard and reputation.of Chinese medicines. The
recognition as a pioneer in the field should be considered a
non-monetary gain. Moreover, the financial problem is not
insolvable. The government would be a good benficiary, since it
can help develop the service to help it formulate policies to
regulate Chinese medicines, as well as gain access to the services
on a more cost-effective basis. An endowment fund from a funding
agency, such as the Royal Hong Kong Jockey Club Foundation and the
Asian Foundation, is another possibility.
Even if fundings are not available, we recommend the Centre
to continue doing research on the authentication, standardization
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and quality control of Chinese medicines. The results will help
overcome the weakness of Chinese medicines and prevent misuse and
abuses of such medicaments. Without such technology and services,
the government is basically handicapped to do anything on
regulating Chinese medicines, even if the Basic Law may require
it. Moreover, the increasing sentiments and consciousness for
consumer protection in developed countries may demand for stricter
regulations on these materials. Without testing and certifying
services, our exporters would have difficulty in satisfying the
customs and drug-inspection agencies in those countries by then,
our trading capacity and capability will be unfavorably affected.
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APPENDIX TABLE 1
CRUDE DRUGS EXPORTED FROM HONG KONG IN 1983
HK4Quantity (Kg)
A) Codonopsis tangshen (292412
Mexic 12 825
B) Astragalus membranaceus (292413)
Mexico 9 4,950







New Zealand 60 2,571
Australia 113 2,441
D) Horns, Antlers etc. (291161)
Taiwan 22,702 86,510
China 6,000 6,507
E) Ivory waste (291166)
Thailand 1,596 120,189
China 500 38,000
F) Ginger dried (075260)
454 9,166USA
Source: 1983 Hong Kong Trade Statistics,.
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APPENDIX TABLE 2
FORMULATED (OTC) CHINESE MEDICINES EXPORTED
FROM HONG KONG IN 1983
Country HK$ Country HK
Nigeria 48,118,460 Australia 94,300
Singapore 19,861,586 Burma 90,698
Malaysia West 16,982,293 Liberia 88,983
China 16,663,747 Germany Fed. Rep. 85,612
Thailand 8,471,162 Switzerland 76,600
USA 6,676,678 Peru 51,000
Philippines 5,582,319 Papus Newguinea 43,558
4,663,775Macau Gambia 29,994
Taiwan 4,229,490 South Africa 28,321
Canada 1,624,944 Fr. Neth. W. Ind. 25,400
678,804Sabah Brunei 23,163
Surinam 584,115 Djibouti 19,600
352,600El Salvador Ecuador 16,800
Oceania Nes 320,777 Guatemala 16,000
294,455Sarawak Oman 15,700
Panama 280,942 Japan 15,000
Honduras 264,000 Haiti 13,716
262,498Mauritius New Zealand 13,107
Trindad Tobago 216,482 United Kingdom 12,912
211,865Indonesia Sweden 11,245
206,349Yemem Arab Republic Seychelles 10,08()
U. Arab Emirates 185,814 Congo People's Rep, 6,890
Netherlands 169,331 US Oceania 5,142
Fiji 150,389 Bahrain 3,500
Trust Ter Pac IsGrenada W. Ind. S. 142,005 2,750
ParaguayDov..Lnican Republic 108,942 1,120
DenmarkA'.uba 830107,300
101,967Barbados
Source: Entry 541798 of the 1983 Hong Kong Trade Statistics.
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APPEIIDIX TABLE 3
MEDICATED WINE CEICNESE TYPE EXPORTED FROM




Source: Entry 541790 of the 1983 Hong Kong Trade Statistics.
85
APPENDIX TABLE 4
CRUDE MEDICINES RE-EXPORTED FROM
HONG KONG TN 19R_
HKQuantity (Kg)
A) Poppy straw (292404)
China 11.935 179,02E
B) Liquorice Root (292410
Rep of Korea 263,701 2,930,74E
Italy 200,00( 1,506,260
Taiwan 171,66: 1,505,942
Japan 123, 49: 886,078
Singapore 33,0E 552,784
USA 5, 20] 150,303
China 8, 37 97,084




Malaysia West 27E 5,297
Sarawak 42E 4,505
Canada 17? 4,000
United Kingdom 9r, 1,750


















ADDendi Tah1e 4 (r nn-IA_1
Quantity (Kg) IIK$











United Kingdom 24 3,600
Mauritius 24 3,048
Belgium Luxem 10 1,800
Papus Newguinea 2 351
E) Astragalus membranaceus (292413)
Taiwan 110, 676 19,084,60!
China 166,517 4,264,401
Singapore 14,305 3,492,41:
Rep of Korea 39,900 868,67
USA 8,499 678, 07-
Canada 2,776 333,31`.
319,58(Macau 19,670























Appendix Table 4 (Cont'd.)
HK$Quantity (Kg)
G) Rehmannia glutinosa (292415)
Taiwan 181,528 2,753,175






Sarawah 1, 371 22,820
Malaysia West 1,003 18,827
France 530 17,139







Malaysia West 3,494 246,863
Canada 1,071 89,430









Maori t-is 4 410
















Appendix Table 4 (Cont'd
Quantity (Kg) HK$
J) Ginseng (292402)
China 102., 420 76,272,746
Singapore 56,254 69,056,344
















United Kingdom 9 3,600
Rep. of Korea 3 3,420
Netherlands 6 2,802
Papua New Guinea 1 2,700




Indonesia 1,000 180, 000
1Malaysia West 2 ,517













Appendix Table 4 (Cont'd.)
Quantity (Kq) HK$
N) Shell Mollusc (291152




Korea D.P.R. 3,500 147,350
China 34,762 82,343





0) Horns Antlers etc. (291161)











Trindad Tobago 339 239, 22C
China 326 220,35c.
France 126 96,224
Philippines 450 92 ,160
Malaysia West 163 63, 710
Korea D.P.R. 9 53,800
United Kingdom 53 40,290
Thailand 147 37,125
Panama 45 31,000
Rep. of Korea 43 20,218
Fr. Neth. W. Ind. 3 13,800
Sarawak 62 11,862
Netherlands 11 7,700
South Africa 6 7,150
Belgium Luxem 11 7,056
5Switzerland 6,500



















South Africa 1,140 48,806
S) Nutmeg and Mace (075242
China 10, 000 138,000
T) Ginger Dried (075260)
Singapore 119,173 1,173,945
Germany Red. Rep 48,654 509,469
Japan 47,030 442,815













Appendix Table 4 (Cont'd.)
Quantity (Kg) HK$
V) Thyme and other spices (0752E)9
Singapore 8,985,435 64,572,452
Thailand 2,564,528 16,886,949
Rep. of Korea 1,046,689 7,480,431






United Kingdom 34,548 394,995
U. Arab Emirates 12,000 318,500
Saudi Arabia 20,060 308,363




Trinidad Tobago 10,797 123,342







Papua New Guinea 410 17,168
Belgium Luxem 1,027 15,787
Bahrain 2,000 14, 000
New Zealand 258 5,677








Appendix Table 4 (Cont'd.)
Quantity (Kq) HK$
W) Seeds of Anise, Badian, Fennel,











South Africa 21,000 126,354
Sweden 20,000 120,393
United Kingdom 7,077 107,820







Malaysia West 3,000 27,000
Peru 650 19,180








India 943, 79C 21,387,72'
Pakistan 381,000 8,248,77,
U. Arab Emirates 384,30C 7,471,53
Saudi Arabia 303,754 7,033,75!
Japan 341,211 6,874,36,
Kuwait 153,691 3,468,87(
Rep. of Korea 175,265 3,036,22
USA 130,768 2,154,32:




Macau 119,678 879, 98:
Morocco 38,500 852,03_`
South Africa 30,000 662,68c,
Isreal 29,950 597,30(
Yemen Arab Rep. 31,112 491, 41f
Cyperus 20,000 420,50C
Taiwan 73,394 327,62E
Korea D.P.R. 10, 000 250,00C
Syria 10,000 237,79C
Germany Fed. Rep. 3,957 111,141




Malaysia West 555 11,222
Australia 100 1,835
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Appendix Table 4 (Cont'd.)
Quantity (Kg) HK$
Y) Pepper and Pimento (0785100
Germany Fed. Rep. 381,095 4,319,92'
Macau 288,971 3,199,29'
United Kingdom 170,215 2,821179!
Philippines 270,792 2,544,29:
USA 124,926 1,650,28!
Rep. of Korea 88,282 689,71:
China 29,304 290,15!
Singapore 20,328 217,t74,'
Belgium Luxem 14,560 187,38
Japan 19,056 177,96
Canada 3,670 84,76E
Saudi Arabia 51110 84,73
Peninsula Spain 9,834 76,70E









Fr. Neth. W. Ind. 22 878
25,526
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Appendix Table 4 (Cont'd.
Quantity (Kg) HK












Malaysia West 228,710 7,236,301
Philippines 130,937 3,590,201






Saudi Arabia 913 989,466









New Zealand 4,117 152,799




South Africa 866 61,374






Belgium Luxem 708 24,646
Isreal 4,000 24,300
Fr. Neth. W. Ind 148 20,820
Oatar 5 20,000
Nauru 510 19,500
Trinidad Tobago 160 8,104
Solomon Islands 484 8,038
123Libya 6,131
12Malagasy Rep. 1,900
5Papua New Guinea 682






MEDICAMENTS NES CHINESE TYPE (FORMULATED (OTC) CHINESE
MEDICINES) RE-EXPORTED FROM HONG KONG IN 1983
Country HK$ Country HK$
Nigeria 27,622,888 Fiji 99,955
Singapore 19,203,281 Zaire Kinshasa 94,211
Indonesia 9,967,603 Fr. Neth. W. Inc 93,573
USA 6,523,425 Switzerland 93,379
China 6,302,441 Panama 741,839
Canada 4,517,937 Paraguay 73,222
Philippines 4,272,462 Sabah 72,255
Macau 2,625,328 Sarawak 52,300
Tait an 2,265,656 Germany Fed. Rej 51,367
NFtherlands 1,207,683 New Zealand 40,717
Australia 980,338 Sweden 36,959
Trinided Tobago 742,108 Cameroom Rep. 36,524
Malaysia West 669,278 Papua Newguinea 26,338
Oceania nes 626,449 Curacao 24,277
Belgium Luxerr 606,797 U. Arab Emirtes 22,500
Japan 456,670 Portugal 21,466
Thailand 340, 4 97 Congo Peo. Rep. 20,280
Korea D.P.R. 271,295 Peninsula Spain 10,343
Greece 251,062 Norway 10,006
Peru 232,280 Italy 9,450
United Kingdc 224,909 Jamaica 5,650
France 221,209 India 4,177
US Oceania 213,367 Venezuela 3,540
Mauritius 204,988 Denmark 2,660
Liberia 193,852 Rep. of Korea 2,600
Buram 162,265 Solomon Islands 2,400
150, 584South Africa Sierra Leone 1,500
Source: Entry 541798 of the 1983 Hong Kong Trade Statistics.
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APPENDIX TABLE 6
MEDICATED WINE CHINESE TYPE RE-EXPORTED






USA 11,453 284, 230
Australia 11,637 272,492
Malaysia West 8,400 208,200
Japan 7,300 110,492
Macau 1,823 96,729
Yemem Arab Republic 2,104 68,256
China 1, 349 58,200
Sabah 1,502 58,041





Thailand 1, 536 20,500
Panama 887 12,206
Fr. Neth. W. Ind. 225 12,150
Fiji 78 7,200
Curacao 100 2,938
New Zealand 21 824
Source: Entry 541790 of the 1983 Hong Kong Trade Statistics
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52-58 DES VOEUX ROAD, W
TOTH FLOOR FLATS A.D
HONG KONG
5-188251TEL. 5-188252
司 公 限 有
CHINESE MEDICINE MERCHANTS ASSOCIATION LTD
14th Hovember, 1983
Mossrs. Tai Sun Trading Co.,
14th Floor,Flat D,Ham Pak Hong Bldg.,
24 Bonham Strect West,
Hong Kong.
Dear Sirs,
We hereby would like to cortify the origin of the following items
which are expored by hessrs.Tai Sun Tradng Company to Sydney
(Australia) per vessel named "
sailing on or about
24th Hovember,1983 as belows:-
Goods of China Origin:
Yook Jook-Palygonatum Officinalo A
King Kai-Hepeta Japonica Maxim
Lon Kow-Forsythia Suspensa Valil
Yok Moo Cho-Leonurus Sibiricus L
Har Goo Cho-Prunclla Vulgaris L
Hun Far-Lonicera Japonica Thunb
Dong Quai-Ligustium Acutislo Bum Scib et Zuce
Doo Chung-Encommia Ulmoides Oliv
Choon Kung Pin-Conioselium Unvittatum Turez
Fong Foong Pin-Silver Divanictum Benth Ethook Fig
Gat Gung Pin-PLatycoden Grandiflorus Do
Goe Hoo Pin-Anemarrhena Asphodelsides Bunge
Gum Cho Pin-Glycyrrhiza Glabra L
Lo Hnn Kuo
Sook Dee-Rohmannio Glutinosa Libosch
Win San-Diescoren Japonica Thunb
Chan Pee-Citrus Mobilis Lour
Yun Chan-Artemisia Capillaris Thunb
Pak Kee-Astraglus Henryi Oliv
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52-58. DESVOEUX ROAD, W.








司 公 限 有







































































































































香 港 中 文 大 學




本 問 卷 旨 在 調 查 中 藥 業 於 買 賣 及 貿 易 藥 材 成 藥
時 有 否 需 要 檢 查 及 證 明 貨 品 之 質 量 ， 成 份 及 效 用 。 資
料 來 源 一 律 保 密 。 填 答 后 ， 請 將 問 卷 撤 回 沙 田 香 港 中
文 大 學 中 藥 研 究 中 心 。 謝 謝 貴 公 司 的 協 助 。





































( 丙 ） 為 擴 展 業 務 ， 開 拓 市 場 ， 貴 公 司 最 希 望 香 港 能 提 供 那 些 服 務
（ 請 刪 去 不 適 用 者 ）
（ 一 ） 核 驗 藥 材 品 種
（ 二 ） 核 驗 成 藥 內 含 之 藥 材 種 類
（ 三 ） 檢 查 油 色 香 味 等
（ 四 ） 檢 查 殘 存 農 藥
（ 五 ） 檢 查 重 金 屬 含 量
（ 六 ） 檢 查 有 效 成 份 之 種 類
（ 七 ） 檢 查 有 效 成 份 之 含 量
（ 八 ） 檢 查 有 否 長 霉 及 蟲 蝕
（ 九 ） 檢 查 難 物 含 量
（ 十 ） 檢 查 包 裝 及 說 明
（ 十 一 ） 檢 查 毒 性
（ 十 二 ） 證 明 功 效
（ 十 三 ） 品 質 控 制
需 要 / 不 必
需 要 / 不 必
需 要 / 不 必
需 要 / 不 必
需 要 / 不 必
需 要 / 不 必
需 要 / 不 必
需 要 / 不 必
需 要 / 不 必
需 要 / 不 必
需 要 / 不 必
需 要 / 不 必
需 要 / 不 必
（ 戊 ） 有 那 些 國 家 之 買 家 需 要 　 貴 公 司 提 供 質 量 證 明 書 。
（ 已 ） 貴 公 司 是 否 滿 意 在 港 之 核 驗 機 構 之 服 務 ？ 　 是 / 否
（ 丁 ） 目 前 　 貴 公 司 一 年 中 有 多 少 次 需 要 核 驗 藥 材 及 成 藥 貨 品 的 服 務 ？
次
（ 　 完 　 ）
再 次 謝 謝 　 　 貴 公 司 的 協 助 。
如 果 　 　 貴 公 司 希 望 獲 取 一 份 是 次 調 查 的 報 告 或 咨
詢 有 關 上 述 服 務 的 資 料 ， 請 將 意 見 及 　 　 貴 公 司 之 名 片
貼 於 下 面 空 白 處
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QUESTIONNAIRE
(B)
Thank you for your kind assistance in filling out this questionnaire.
Information supplied will be kept confidential as to its source
Kindly return the questionnaire using the enclosed stamped envelope before
April 25, 1985 to the Chinese Meditinal Material Research Centre, The
CHinese University of Hong Kong, Shatin, N.T., Hong Kong
A) Does Your company need a dependable source of service for
the followings:
a) Authentication of crude Chinese medicines ( 药 材 ）
to their original plant and animal source (e.g. ginseng
to Panax ginseng)
b) Authentication of formulated CHinese medicines
( 成 药 ）
to their constituent plants and animals (e.g. Ginseng
Tea to Panax ginseng)
c)Certify the quality of Chinese medicines using traditional or
organolpetic parameters (e.g. colour and smell)
d) Determine the amount of residue pesticide present in
Chinese medicines (e.g. DDT)
e)Determine the amount of heary metals present (e.g. mercury)
f)Qualitatively determine if a specific bioactive component
is present in Chinese medicines (e.g. ginsenoside)
g) Quantitatively determine the amount of a specific bioactive
component present in Chinese medicines (e.g. ginsenoside)
h) Determine the presence of micro-organisms and mycotoxins
i)Check the presence of foreign substances
j)Jndertake toxicity tests (e.g. LD50 in mice)
B)Currently, do you know of a dependable source of
service for the above-mentioned subjects(if YES, please specify)
a) Authentication of crude CHinese medicines ( 药 材 ）
YES at
b) Authentication of formulated CHinese medicines ( 成 药 ）
YES at
c) Certify the quality of Chinese medicines using traditional or
organoleptic parameters
YES at



























e) Determine the amount of heavy metals present
YES at
f) Qualitatively determine the presence of bioactive components
YES at
g)Quantitatively determine the amount of bioactive components
YES at
h) Dtermine the presence of micro-organisms and mycotoxins
YES at
i) Check the presence of foreign substances
YES at
j) Undertake toxicity tests
YES at
c) Do you know if there is any demand for the above-mentioned services
a) Authentication of crude Chinese medicines ( 药 材 ）
b) Authentication of formulated Chinese medicines （ 成 药 ）
c) Certify the quality of Chinese medicines using traditional
or organoleptic parameters
d) Dtermine the amount of regidue pesticide present in
Chinese medicines
e) Determine the amount of heavy metals present
f) Qualitative determination of bioactive components
g)Quantitative determination of bioactive components
h) Dtermine the presence of micro-organisms and mycotoxin
i) Check the presence of foreign substances
j) Undertake toxicity tests
D) Do you foresee any future increase in demand for the above-mentioned
services?
a)Authentication of crude Chinese medicines （ 药 材 ）
b) Authentication of formulated Chinese medicines ( 成 药 ）
c)Certify the quality of Chinese medicines using
traditional or organoleptic parameters




































e) Determine the amount of heavy metals present YES NO
f) Qualitative determination of bioactive components YES NO
g) Quantitative determination of bioactive components YES NC
h) Determine the presence of micro-organisms and mycotoxin YES NO
i) Check the presence of foreign substances YES NO
i) Undertake toxicity tests YES NO
E) Personally do you think Hong Kong should have stricter
regulation on the authenticity, quality and safety of
Chinese crude and formulated medicines? YES NO
END
Thank you again for your kind assistance.
If you prefer to have a copy of our report on this survey, please





Thank you for your kind assistance in filling out this questionnaire.
Information supplied will be kept confidential as to its source.
Kindly return the questionnaire using the enclosed stamped envelope before
April 25, 1985 to the Chinese Medicinal Material Research Gentre, The
Chinese University of Hong Kong, Shatin, N.T., Hong Kong
A)Does your company offer the following services on crude
Chinese medicines
( 药 材 ）
a)Authenticate the materials to their original plant
and animal source (e.g. Ginseng to Panax ginseng)
b)Certify the quality of the materials using traditional
or organoleptic parameters (e.g. colour and smell)
c)Determine the amount of residue pesticide present
(e.g. DDT)
d)Dtermine the amount of heavy metals present
(e.g. mercury)
e)Qualitatively determine if a specific bioactive
component is present (e.g. ginsenoside)
f) Quantitatively determine the amount of a specific
bioactive component present (e.g. ginsenoside)
g)Determine the presence of mycotoxins
h) Check the presence of foreign substances
i)Undertake toxicity tests (e.g. LD50 in mice)
B)For those services currently not offered by your company
(ie. marked NO in question A), do you expect your company
to start offering them in the next three years
C) How frequently does your company receive requests for service
on crude CHinese medicines ( 药 材 ） ？
NEVER ONCE/day ONCE/week ONCE/month
ONCE/quarter ONCE/half year ONCE/year
D) Does your company offer the rollowing services on formulated
Chinese medicines ( 成 药 ） ？
a)Authenticate the materials to their constituent plants
and animals (e.g. Ginseng Tea to Panax ginseng)
b)Certify the quality of the materials using traditional
or organoleptic parameters (e.g. colour and smell)































d) Determine the amount of heavy metals present
(e.g. mercury)
e) Qualitatively determine if a specific bioactive
component is present (e.g. ginsenoside)
f) Quantitatively determine the amount of a specific
bioactive component present. (e.g. Rinsenn iriP)
g) Determine the presence of m.Icro-organisms
h) Check the presence of foreign substance
i) Check the nature of coating on tablet/ ill
j) Check the tablet/pill disintegration rime
E) Check the tablet/pill weight variation
I) Undertake toxicity tests (e.g. LD50 in mice)
E) For those service currently not offered by your company
(ie. marked NO in question D), do you expect your company
to start offering them in the next three vE?arc9
F) How frequently does your company receive requests for service:
on formulated Chinese medicines ( 成 药 ）
NEVER ONCE/day ONCE/week ONCE/month
ONCE/quarter
ONCE/half year ONCE/year
G) Do you foresee an increase in demand for services for the
authentication, standardization and certification of
Chinese medicines?
a) For crude materials （ 药 材 ）
b) For formulated materials （ 成 药 ）
H) Personally do you think Hong Kong should have stricter
regulation on the authenticity, quality and safety of
Chinese crude and formulated medicines?
END
Thank you again for your kind assistance.
If you prefer to have a copy of-our report on this survey, please
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